CA2195973A1 - N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines - Google Patents
N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepinesInfo
- Publication number
- CA2195973A1 CA2195973A1 CA002195973A CA2195973A CA2195973A1 CA 2195973 A1 CA2195973 A1 CA 2195973A1 CA 002195973 A CA002195973 A CA 002195973A CA 2195973 A CA2195973 A CA 2195973A CA 2195973 A1 CA2195973 A1 CA 2195973A1
- Authority
- CA
- Canada
- Prior art keywords
- dihydro
- phenyl
- propyl
- oxo
- benzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229940049706 benzodiazepine Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 46
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 22
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims abstract description 10
- -1 chloro, bromo, iodo Chemical group 0.000 claims abstract description 10
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000013078 crystal Substances 0.000 claims abstract description 9
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 9
- 239000001257 hydrogen Substances 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 150000004677 hydrates Chemical class 0.000 claims abstract description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims abstract description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 38
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- 239000003416 antiarrhythmic agent Substances 0.000 claims description 9
- 206010003119 arrhythmia Diseases 0.000 claims description 9
- 230000006793 arrhythmia Effects 0.000 claims description 8
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims description 6
- WLYPBMBWKYALCG-UHFFFAOYSA-N [2,4-bis(trifluoromethyl)phenyl]boronic acid Chemical group OB(O)C1=CC=C(C(F)(F)F)C=C1C(F)(F)F WLYPBMBWKYALCG-UHFFFAOYSA-N 0.000 claims description 5
- 239000002327 cardiovascular agent Substances 0.000 claims description 5
- 229940125692 cardiovascular agent Drugs 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 150000003857 carboxamides Chemical class 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003937 drug carrier Substances 0.000 claims 2
- KSSUPPZSQRHORL-UHFFFAOYSA-N 2-[2,4-bis(trifluoromethyl)phenyl]-n-(2-oxo-5-phenyl-1-propan-2-yl-3h-1,4-benzodiazepin-3-yl)acetamide Chemical compound O=C1N(C(C)C)C2=CC=CC=C2C(C=2C=CC=CC=2)=NC1NC(=O)CC1=CC=C(C(F)(F)F)C=C1C(F)(F)F KSSUPPZSQRHORL-UHFFFAOYSA-N 0.000 claims 1
- RFHOUGBBBSXAOM-UHFFFAOYSA-N 3,4-dichloro-n-[5-(2-fluorophenyl)-2-oxo-1-propan-2-yl-3h-1,4-benzodiazepin-3-yl]benzamide Chemical compound O=C1N(C(C)C)C2=CC=CC=C2C(C=2C(=CC=CC=2)F)=NC1NC(=O)C1=CC=C(Cl)C(Cl)=C1 RFHOUGBBBSXAOM-UHFFFAOYSA-N 0.000 claims 1
- LMMDFMXKXGPJPR-UHFFFAOYSA-N 3-cyclohexyl-n-[5-(2-fluorophenyl)-2-oxo-1-propan-2-yl-3h-1,4-benzodiazepin-3-yl]propanamide Chemical compound O=C1N(C(C)C)C2=CC=CC=C2C(C=2C(=CC=CC=2)F)=NC1NC(=O)CCC1CCCCC1 LMMDFMXKXGPJPR-UHFFFAOYSA-N 0.000 claims 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical compound CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 93
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 54
- 235000019439 ethyl acetate Nutrition 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 229910001868 water Inorganic materials 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- 101150041968 CDC13 gene Proteins 0.000 description 10
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000006260 foam Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000000747 cardiac effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 235000017557 sodium bicarbonate Nutrition 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- BCHGLBXVODTIEE-UHFFFAOYSA-N 2-[2,4-bis(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(C(F)(F)F)C=C1C(F)(F)F BCHGLBXVODTIEE-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000036982 action potential Effects 0.000 description 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 description 3
- 229960002370 sotalol Drugs 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 3
- 208000003663 ventricular fibrillation Diseases 0.000 description 3
- KKKKZZBJYUIHES-UHFFFAOYSA-N 3-amino-5-phenyl-1-propan-2-yl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(N)C(=O)N(C(C)C)C2=CC=CC=C2C=1C1=CC=CC=C1 KKKKZZBJYUIHES-UHFFFAOYSA-N 0.000 description 2
- 239000005541 ACE inhibitor Substances 0.000 description 2
- ITPDYQOUSLNIHG-UHFFFAOYSA-N Amiodarone hydrochloride Chemical compound [Cl-].CCCCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(I)=C(OCC[NH+](CC)CC)C(I)=C1 ITPDYQOUSLNIHG-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- 241000080590 Niso Species 0.000 description 2
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 2
- 235000011613 Pinus brutia Nutrition 0.000 description 2
- 241000018646 Pinus brutia Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 229960005260 amiodarone Drugs 0.000 description 2
- 230000003288 anthiarrhythmic effect Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- MAOBFOXLCJIFLV-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanone Chemical compound NC1=CC=CC=C1C(=O)C1=CC=CC=C1 MAOBFOXLCJIFLV-UHFFFAOYSA-N 0.000 description 1
- ZYJPUMXJBDHSIF-LLVKDONJSA-N (2r)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-LLVKDONJSA-N 0.000 description 1
- BUJAGSGYPOAWEI-SECBINFHSA-N (2r)-2-amino-n-(2,6-dimethylphenyl)propanamide Chemical compound C[C@@H](N)C(=O)NC1=C(C)C=CC=C1C BUJAGSGYPOAWEI-SECBINFHSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- GUJAGMICFDYKNR-UHFFFAOYSA-N 1,4-benzodiazepine Chemical compound N1C=CN=CC2=CC=CC=C12 GUJAGMICFDYKNR-UHFFFAOYSA-N 0.000 description 1
- SWFFFUJOWAJJCH-UHFFFAOYSA-N 1-(bromomethyl)-2,4-bis(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(CBr)C(C(F)(F)F)=C1 SWFFFUJOWAJJCH-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- RQKXUWGXSNMDDS-UHFFFAOYSA-N 2,4-bis(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=C(C#N)C(C(F)(F)F)=C1 RQKXUWGXSNMDDS-UHFFFAOYSA-N 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- CXKCZFDUOYMOOP-UHFFFAOYSA-N 3,5-dichlorobenzoic acid Chemical compound OC(=O)C1=CC(Cl)=CC(Cl)=C1 CXKCZFDUOYMOOP-UHFFFAOYSA-N 0.000 description 1
- OVDAJNDXPCYKEA-UHFFFAOYSA-N 3-azido-5-phenyl-1-propan-2-yl-3h-1,4-benzodiazepin-2-one Chemical compound N=1C(N=[N+]=[N-])C(=O)N(C(C)C)C2=CC=CC=C2C=1C1=CC=CC=C1 OVDAJNDXPCYKEA-UHFFFAOYSA-N 0.000 description 1
- 229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
- 229940123413 Angiotensin II antagonist Drugs 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000208011 Digitalis Species 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- KLDXJTOLSGUMSJ-JGWLITMVSA-N Isosorbide Chemical compound O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 KLDXJTOLSGUMSJ-JGWLITMVSA-N 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 206010069140 Myocardial depression Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010052164 Sodium Channels Proteins 0.000 description 1
- 102000018674 Sodium Channels Human genes 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 description 1
- 229960000571 acetazolamide Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 229960002624 bretylium tosilate Drugs 0.000 description 1
- KVWNWTZZBKCOPM-UHFFFAOYSA-M bretylium tosylate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.CC[N+](C)(C)CC1=CC=CC=C1Br KVWNWTZZBKCOPM-UHFFFAOYSA-M 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960000830 captopril Drugs 0.000 description 1
- FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
- 230000003684 cardiac depression Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 1
- 229960004166 diltiazem Drugs 0.000 description 1
- UVTNFZQICZKOEM-UHFFFAOYSA-N disopyramide Chemical compound C=1C=CC=NC=1C(C(N)=O)(CCN(C(C)C)C(C)C)C1=CC=CC=C1 UVTNFZQICZKOEM-UHFFFAOYSA-N 0.000 description 1
- 229960001066 disopyramide Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000037024 effective refractory period Effects 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 229960002003 hydrochlorothiazide Drugs 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229960002479 isosorbide Drugs 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- CZRQXSDBMCMPNJ-ZUIPZQNBSA-N lisinopril dihydrate Chemical compound O.O.C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 CZRQXSDBMCMPNJ-ZUIPZQNBSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 229960001789 papaverine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 238000000306 qrs interval Methods 0.000 description 1
- 210000001567 regular cardiac muscle cell of ventricle Anatomy 0.000 description 1
- 230000002336 repolarization Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 229960002872 tocainide Drugs 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Abstract
This invention is concerned with novel compounds represented by structural formula (I), where R1 is formula (II) or (III); X and Y are independently hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl; n is 0, 1 or 2; and R2 is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy; as the racemates, mixtures of enantiomers, individual diastereomers or individual enantiomers, and pharmaceutically acceptable crystal forms, salts, or hydrates thereof.
Description
_ WO 96/05827 . PCT/US95/10501 ~ 2195973 TITLE OF THE INVENTION
N-2,3-DIHYDRO- 1 -(2-PROPYL)-2-OXO-5-PHENYL- 1 H- 1 ,4-BENZODL~ZEPINES
Arrhythmias often occur as complications to cardiac diseases such as myocardial infarction and heart failure. In a serious case, ~hyll~ ias give rise to ventricular fibrillation and can cause sudden death.
Though various antia"yll",-ic agents are now available on the market, agents which exhibit both satisfactory effects and high safety profiles have not been obtained. For example, antiarrythmic agents of Class I, according to the cl~c~ific~ion of Vaughan-Williams, which cause a selective inhibition of the m~ximllm velocity of the upstroke of the 15 action potential (Vmax) are in:~tleqll~t~ for preventing ventricular fibril-lation. In addition, they have problems regardmg safety, namely, they cause a depression of the myocardial contractility and have a tendency to induce arrythmias due to an inhibition of the impulse conduction. Beta-adrenoceptor blockers and calcium antagonists which belong to Class Il 2 o and IV respectively, have a defect in that their effects are either limited to a certain type of al,hy~ "ia or are contr~3in~ tPd because of their cardiac de~ sal,i properties in certain patients with cardiovascular disease. Their safety, however, is higher than that of the antiarrhythmic agents of Class 1.
Antiarrythmic agents of Class III are drugs which cause a selective prolongation of the duration of the action potential without a ~ignific~nt depression of the Vmax. Drugs in this class are limited.
Examples such as sotalol and arniodarone have been shown to possess Class III properties. Sotalol also possesses Class II effects which may 3 o cause cardiac depression and be contraindicated in certain susceptible patients. Also, amiodarone is severely limited by side effects. Drugs of this class are expected to be effective in preventing ventricular fibrilla-tions. Pure Class III agents, by definition, are not considered to cause myocardial depression or an induction of a"l,y~ "ias due to the W096/05827 2 1 959 73 PCT/US95/10501 ~
inhibition of the action potential conduction as seen with Class I
a--iial-l-yll.---ic agents.
SUMMARY OF TH~ INVl~NTION
This invention is concerned with novel compounds ;s~nl~d by structural formula I
~N ~ ~
~:N H (cH2)n ~. , I
where Rl is ~y or ~
X and Y are independently hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl;
nisO, l or2;and R2 is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy;
as the la~~lllal~s, mixtures of enantiomers, individual diastereomers or individual enantiomers, and ph~l " ,~. r~ll ically acceptable crystal forms, salts, or hydrates thereof, which are useful as antiarrhythmic agents.
The compounds of the present invention may have asymmetric centers and occur as r~r~rn:~Pc mixtures of enantiomers, individual diastereomers, or as individual enantiomers with all isomeric _ . . _ . . . . . _ . _ . . . . . _ .
~ WO 96/0582'1 2 ~ 9 5 9 7 3 PCT/US95/10501 forms being included in the present invention. The invention is also concerned with ph~rrn~entir~l formulations ~o~ )flsillg one of the novel compounds as an active ingredient.
The invention is also concerned with a method of treating 5 arrhythmia by the ad.~ ion of one of the novel compounds or formulation thereof to a patient in need of such treatment.
DETAILED DESCRIPTION OF THE INVENTION
The novel compounds of this invention have structural 10 formula ~N ~ ~
~-cN H (CH2)n where Rl is ~y or ~
X and Y are in~PpP.n~ ntly hydrogen, fluoro, chloro, b}omo, iodo, or trifluoromethyl;
30 nisO, I or2;and R2 is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy;
as the r~rl~m~t~s, mixtures of en~ntiomPrs, individual diastereomers or individual enantiomers, and pl-," " ,;~,,1 ically acceptable crystal forms, wos6/oss27 2~ 95~73 PCIIUS95110501 ~
salts, or hydrates thereof. These compounds include pharm~rent~ ly acceptable crystal forms and hydrates of the compounds of Formula 1, which are ~llialflly~ llic agents.
The compounds of the present invention may have 5 asymmetric centers and occur as racemates, mixtures of enantiomers, individual diastereomers, or as individual ~n~ntiomf rs with all isomeric forms being included in the present invention.
One preferred embodiment of the present invention is (+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~et:~mide ~~ CF
N_~O ~ ~ 3 ~GN H CF3 Another embodiment of the novel compounds of this invention is ~+)-3,5-Dichloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][I ,4]diazepin-3-yl]ltrn7~lmi~
~ O Cl N~ ~ /=<
~5 N) H
A second embodirnent of the novel compounds of this invention is (+)-3-Cyclohexyl-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l,4]diazepin-3-yl]~ d"a",ide ~ WO 96/0S827 2 1 9 5 9 7 3 PCT/U595/lOSOI
s ~$ 1, 10Still another embodiment of the novel compounds of this invention is (+)-2-(3,4-Dichlorophenyl)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][ I ,4]diazepin-3-yl]~ret~mi~
~0 ~ CI
Other examples of the cl ." ,l.""~c of this invention include:
(+)-2-(3,5-Dichlol~Jpllellyl)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1 H-benzo[e] [ I ,4]diazepin-3-yl]~ret?rni-iP
~ Cll N--~~ ~0'C I
3 o \~5N H
WO 96/05827 PCT/US95/10501 ~
(+)-3-(2,4-Dichlorophenyl)-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]lulù~Jdna~llide N H 1~ C I
(-)-3-(2,4-Dichlorophenyl)-N-[3S-2,3-dihydro- 1 -(2-propyl)-2-oxo-5 -phenyl-lH-benzo[e][1,4]diazepin-3-yl]l,-u~ ide ~$H
(-)-3-(3,4-Dichloro)-N-[3S-2,3-dihydro- 1 -(2-propyl)-2-oxû-5-phenyl- 1 H-benzo[e][ I ,4]diazepin-3-yl]bPn7~mi-1.o I~H J~
~ WO 96/05827 21 9 5 9 7 3 PCT0S95110501 (+)-2-Afi,qm,qnt,qn-l-yl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-~ lH-benzo[e][1,4]diazepin-3 yl1qretqmi(le ~N H
(+)-4-Cyclohexyl-N-[3R-2,3 -dihydro- I -(2-propyl)-2-oxo-S-phenyl- I H-benzo[e][l ,4]diazepin-3-yl]bntqnqmi(l-~
_~0 ~~0 (+)-A~qmqntqn- I -yl-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-25 IH-benZO[e][l,4]diaZepill-3-yl]CarbOXalllide 3 0 ~N H
WO 96/0582~ 2 1 ~ 5 9 7 3 PCT/US9~/10~01 (+)-2-[3,5-Bis(trifluoromethyl)phenyl] -N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]~et~mitl~
N H
(+)-2-(2,4-Dichlorophenyl)-N-[3R-2,3-dihydro-l -(2-propyl)-2-oxo-5-phenyl-lH-benzo~e][l ,4]diazepin-3-yl]acetamide ~lal N
(+)-3-Chloro-N-[3R-2,3 -dihydro- I -(2-propyl)-2-oxo-5-phenyl-1 H- 1,4-25 benzodiazepin-3-yl]b~on7~m~
~--~'n'HN)~CI
/CI\ .
~ WO 96/05827 . 2 1 9 5 9 7 3 PCT/US95/10501 (+)-4-Chloro-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH- 1,4-benzodiazepin-3-yl]benzamide .
~0 ~3 (+)-2-(3-Chlorophenyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1 ,4]diazepin-3-yl]~ret:~mi(lt~
~ ~0 ~
(+)-3-Bromo~-chloro-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]dia~epin-3-yl]ben7slmi~1~
~~ ~
W O 96/05827 2 1 q 5 q 7 3 PC~rAUS95/10501 3,4-Dichloro-N-[2,3-dihydro-1 -(2-propyl)-2-oxo-5-(2-fluorophenyl)-1 H-benzo[e][ I ,4~diazepin-3-yl]k~n7.~mide ~~ O
H
o ~F
(+)-3-Bromo-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l74]diazepin-3-yl]b n7.~mi~1~
N ~ Br 2 5 3-Cyclohexyl-N-L2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(2-fluorophenyl)- 1 H-benzo[e][1,4]diazepin-3-yl]p,~ all-ide 3 o ~5~N~O
g~F
~ W0 96/05827 . 2 l 9 5 9 7 3 PCr/USg5ll050l 3-(3,5-Dichloro)-N-[3S-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]ben7.~mi~
~ N H~
(+)-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl- I H- 1,4-b~n70~ 7.f~pin-3-yl]bl~n7.~mi,l,-~ N ~3 g~
(+)-2-(3-Trifluorome~ylphenyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-25 oxo-5-phenyl-lH-benzole][1,4]diazepin-3-yl]~e~lmi-~N H CF3 g~
WO 96/05827 2 1 9 5 9 7 3 PCT/US9511050~ ~
(+)-3,5-Bis(trifluoromethyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-S-phenyl- I H-benzo[e] [ I ,4]diazepin-3 -yl]bPn7.~mide N J~c F3 (+)-2-(2-Trifluoromethylphenyl)-N-[3R-2,3-dihydro- l -(2-propyl)-2-oxo-~-phenyl-lH-benzo[e][l~4]diazepin-3-yl]~ret~ dp N ~3 (+)-2-(4-TrifluululllelllyllJhenyl)-N-~3R-2,3-dihydro-1 -(2-propyl)-2-25 oxo-~-phenyl- 1 H-benzo~e]l I ,4]diazepin-3-yl]~et~mi,l.o ~ ~o ~ ~CF3 ~ WO 96/05827 2 1 9 5 9 7 3 PCT/US95110501 (+)-2-Phenyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[E] [ 1 ,4]diazepin-3-yl]acetamide (-)-2-(3,5-Dichlorophenyl)-N-[3S-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][ I ,4]diazepin-3-yl]acetarnide Cl ¢~=$ N ~ J~C I
~
(-)-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[3R-2,3-dihydro- 1 -(2-2s propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~,~et:~mitllo ~sN H OH CF3 ~ ,~
WO 96105827 2 1 9 5 9 7 3 PCTIUSgSlloSol (+)--2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[3R- I -(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-lH-ben~o[e][l ,4]diazepin-3-yl]:~ret:~mifie .
¢~N O H CF3 ~
(+)-3-Cyclohexyl-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(4-fluoprophenyl)-lH-benzo[e][1,4]diazepin-3-yl]l~lup~lalllide < ~N'~I--'O
(+)-3 ,S-Dichloro-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(4-fluorophenyl)-25 lH-benzo[e][1,4]diazepin-3-yl]h~n7~mi~
~, wo 96/0s827 2 1 9 5 9 7 3 PcTrusg5rlo501 ~ O
~ Cl F
A novel process for preparing the compounds of this invention is srhPm:~rir~lly exemplified below im scheme, and these steps are well known in the art and/or described in the Examples that follow.
W096/05827 . ~1 95~73 PCWS95110501 Scheme 1 HN~O iPr-l ~N~
~ N Cs2CO3 ~ N
~,N KHMDS
i o ~.~N~ N~
~J~ NH2 P(Ph)3 ~/ ~N3 ~N . \~N
\ D-Boc-Phe-OH, EDC, HOBT
~N
¢~N H NHBoc HCI (9) ~ WO 96/05827 2 1 9 5 9 7 3 PCT/US95/lOSOI
Scheme 1 cont'd.
¢~H ~'z ¦ Separate Diaste~omers ~5~NH-D-Phe-H 1~ IH-D-Phe-H
~ ' 1 . 1) PhNCS
~ 2) TFA _~
NH2 [~ ~ NH2 ~N ~N
R(CH2)nCOCI or R(CH2)nCO2H, EDC, HOBT , /
N~ (CH2)n~R ¢~ N~ (CH2)n-R
R = O ; ~ X X~Y= H, Cl, CF3, Br WO 96/05827 2 1 ~ 5 9 7 3 PCT/US95110501 The novel compounds of the present invention have the pharmacological properties required for antiarrhythmic agents of C~lass III, namely they demonstrate prolongation of QTc-interval, and dose dependent increases im ventricular refractoriness. This is accom-plished without effecting heart rate, mean arterial pressure and PR and QRS intervals. Modest increases in LV+dPldt (left ventricular change im pressure with time) is observed. Further, these compounds suppress the induction of PVS (Programmed Ventricular Stimulation) induced o ventricular tachyarrhythmias.
These compounds are effective in treating and preventing all types of a-lllyll~--ias including ventricular and atrial (supraventricular) arrhythmias. The compounds of the present invention are especially useful to control reentrant arrhythmias and prevent sudden death due to the ventricular fihrill~tinn These compounds are also effective in treating and preventing impaired cardiac pump functions.
In the novel method of this invention of treating arrhythmia, one of the compounds or pl~ c~ icsllly acceptable salt thereof, is ~.l,,,;,,i~l~,c~d in an amount ranging from about .0001 to about 10 mg per kg of body weight per day, preferably from about .0001 to about 2 mg per kg of body weight per day, and more preferably by iu~ wus delivery of from about 0.0003 to about 0.3 mg per kg of body weight per day, or when given orally from about 0.03 to about I mg per kg of body weight per day, in a single dose or in 2 to 4 divided doses.
These compounds, orpl~ ",;~.~elll;r~lly acceptable salts thereof, in the described dosages, are ~ cd orally, iullldlue,ilu"e-ally, ,suh.~ l.Pously, intr~mll~clll~rly, transdermally, sublingually or intravenously. They are preferably ~lmini~ti~red intravenously or orally, for example in the form of tablets, troches, capsules, elixirs, ~u~)en~iùns, 3 0 ~mnl~ion~ syrups, wafers, chewing gum, or the like prepared by art recognized procedures. The amount of active compound in such thera-peutically useful compositions or preparations is such that a suitable dosage will be obtained.
~ WO 96/05827 2 1 9 5 ~ 7 3 PCT/US95110501 These compounds can be ~mini~t~red as the sole active ingredient or in combination with other antiarrhythmic agents or other ~ cardiovascular agents, such as Class 1, Class Il or Class IV antiarrhythmic agents, vasodilators, angiotensin converting enzyme inhibitors, 5 angiotensin II antagonists, diuretics or digitalis.
These compoumds can be :~(iminist~red as a method of treat-ing arrhythmia and impaired cardiac pump functions in conjunction with defibrillators, including implantable defibrillators. These compounds reduce the frequency of defibrillator firing.
By Class I ~l~iallhyllllllic agents is meant those agents which provide for sodium channel blockade, mcluding those compounds which exert a ~llellJl,ldlle stabilizing effect. Exemplary of this class of compounds are qlliniriin~ l,lu':Ai~ ie, disopyramide, lidocane, tocainide, flt-r~ini(1~- and plulJdrt;llolle. By Class Il ~lliallhyllllllic compounds is meant those agents which block symp~thf~ti~ activity.
Exemplary of this class of compounds are propranolol and acebutolol.
By Class m antiarrhythmic agents is meant those compounds which prolong the effective refractory period without altering the resting membrane potential or rate of depolarization. In addition to the novel 20 compounds of this invention, compounds such as amiodarone, bretylium and sotalol are considered to be in this class. Class IV allliallhyllllllic agents are effective in calcium channel blockade. Exemplary of this class of compounds are diltiazem and verapamil. Further definition of these classes can be found in Pharma Projects, section CIB, May 1993, which 25 is hereby incul~,uldl~d by reference.
Exemplary of vasodilators are compounds such as papaverine and isosorbide dinitrat. Examples of :~ngiot~n~in converting enzyme inhibitors include enalapril, lisinopril and captopril. Examples of diuretics include hydrochlorothiazide and acetazolamide. The pharma-3 0 ceutical agents listed herein are examples and do not represent a completelisting of the many compounds in these classes which are contemplated by this invention.
The activity of the compounds described herein as antiarrhythmic agents is measured by their ability to block the IKS
27 95~3 and IKr currents as .1~ t~rminf~d by the following test protocol.
Outward potassium currents are measured in single guinea pig ventricular myocytes using a whole-cell voltage clamp technique described in detail elsewhere (~qn~in~tti and Jurkiewicz, 1990, Two 5 components of cardiac delayed rectifier K+ current: differential se~ ivily to block by Class m ~lliallhy~ llic agents. J. Gen Physiol.
96: 195-215). Myocytes are isolated by enzymatic (collagenase and protease) digestion of T ~ng~ndorf perfused hearts. Single cells are then voltage clamped using I mm square-bore pipettes filled with 0.5 M
gluconate, 25 mM KCI, 5 mM K(2)ATP. Cells are bathed in a solution containing,inmM: 132NaCI,4KCI, 1.2MgC12, 10HEPES, 10glucose:
pH 7.2, temp. 35~C.
Each cell is m~int~inPd at a holding potential of -50 mV.
Test depolarizations are applied as voltage rarnps from -85 to -50 mV, and as steps to -10 mV (0.5 s) and +50 mV (1.0 s). IKI is measured as peak outward current during the voltage ramp. IKr is measured as tail currents upon repolarization from -10 mV to -50 mV. IKS is measured as time-dependent current during the pulse to +50 mV. Currents are measured during control, then after exposure to drug at two different 2 o ~nn(~ntrzltion~
Employing this test the compounds described herein have an ICso of less than 100 nM as IKS blockers. The comounds of this invention are at least 10 times more potent in the blockade of IKS than the blockade of IKr-2s Fxample 1 (+)-3,5-Dichloro-N- [3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl - 1 H-benzo[e][l ,4]diazepin-3-y]]bPn7~mi~
~ WO 96105827 PCTIUS95110501 2l ~5973 ~ N H ~
~ Cl Step A: Preparation of 2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-o lH-benzo[e][1,4]diazepine A solution of S-phenyl-l ,4-ben70~ 7f pine-2-one (J. Org.
Che~r., 1962, 27, 3788)(50 g, 0.21 lmole) in DMF (100 mL) was treated with Cesium carbonate (82.8 g, 0.254mole) and 2-iodup.upd.lf (43.2 g, 5 0.254 mole). The mixture was stirred at room L~ alul~ for five hours.
The reaction mixture was then poured into water (2L) and extracted with ethyl acetate (3 X IL). The combined ethyl acetate fractions were dried over anhydrous m~gnf ~inm sulfate, filtered and concentrated at reduced pressure. The residue was crystallized from ethyl ether to give 45 g (77 20 %) of the product. MP = 153 - 155~C
IH NMR (CDC13) o 7.65-7.6(m, 2H), 7.60-7.35 (m, SH), 7.35-7.20 (m, 2H),4.72(d, J = 10 Hz, lH), 4.58 (hep, J = 6.8 Hz, lH), 3.75 (d,J=lOHz, lH), 1.5(d,J=6.8Hz,3H),1.2(d,J=6.8Hz,3H).
25 Step B: Preparation of 3-Azido-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl- 1 H-benzo[e] [1,4]diazepine To a solution of 2,3-dihydro-1-(2,propyl)-2-oxo-5-phenyl-~ 1 H- 1,4-benzodiazepine (50 g, 0.179 mole) in THF (1200 mL) at -70~C
30 was added a solution of potassium bis(trimethylsilyl) amide in toluene (400 mL of a 0.5 N solution, 0.20 mole). The deep orange solution was then treated with a solution of lliisul,lu~,yll,r"~f .~f~,llfonyl azide (61.1 g,0.197 mole) in THF (200 mL). The reaction was stirred at -70~C for 10 minutes and then treated with acetic acid (4 mL in 20 mL of THF) and WO 96/05827 2 1 9 ~ 9 7 3 PCT/US95110501 warmed to room le-l-peldlul~ over one hour. The reaction mixture was then poured into water (1.5 L) and extracted with ethyl acetate (3 X 500 mL) The combined ethyl acetate fractions were washed with a solution of sodium bicarbonate (300 mL), then water (2 X 500 mL), and then brine 5 (500 mL). The ethyl acetate solution was then dried over anhydrous m~gn~sillm sulfate, filtered and concentrated at reduced pressure. The residue was crystallized from ethyl ether to give 48 g (84 ~o) of the product. MP= 178 - 179~C;
H NMR (CDCI3) o 7.75-7.65(m, 2H), 7.60-7.20 (m, 7H), 4.58 (hep, o J = 6.8 Hz, IH),4.45(s, lH), 1.51 (d, J = 6.8 Hz, 3H), 1.26 (d, J = 6.8 Hz, 3H)-~: Preparation of racemic 3-Amino-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepine To a solution of 3-azido-2,3-dihydro-1-(2,propyl)-2-oxo-5-phenyl-lH-1,4-benzodiazepine (48 g, 0.15 mole) in THF (500 mL) at room l~ ulc; was added water (40 mL) and triphenyl phosphine (90 g, 0.343 mole). The reaction was stirred at room Lt;lll~ iUI~ for 24 hours 20 and conr~nt-~rl-d at reduced pressure. The residue was partitioned between lN H~l (1.5 L) and ether (500 mL). The ether layer was discarded and the aqueous phase was extracted with ethyl acetate ( I X
100 mL) which was also discarded. The aqueous phase was basified to pH 8 by careful addition of 6 N sodium hydroxide solution and extracted 25 with ethyl acetate (3 X 500 mL). The combined ethyl acetate phases were dried over anhydrous m~nf~sillm sulfate, filtered, and cu~). r~ ed at reduced pressure. The residue was crystallized from ethyl ether to give 41.7 g (94 %) of the product. MP = 130-135~C;
lH NMR (CDC13) ~ 7.75-7.65 (m, 2H), 7.60-7.20 (m, 7H), 4.65 (hep, 30 J = 6.8 Hz, lH),4.43 (s~ lH), 2.5 (br s, 2H,-NH2),1.51 (d, J = 6.8 Hz, 3H), 1.26(d,J=6.8Hz,3H).
_ WO 96/05827 PCT/US95/10501 2l 95973 ~ ~ Preparation of (2R)-2-Amino-3-phenyl-N-[2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][1,4]diazepin-3-yl]
propionamide To a stirring solution of ( )-3-amino-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-1,4-b~n7O~ 7l~pine (40.8 g, 139 mmol) in dimethylformamide (140 mL) was added EDC (32.0 g, 167 mmol), HOBT (22.6 g, 167 mmol) and N-BOC-D-phenylalanine (44.3 g, 167 mmol). This was stirred at ambient l~ eld~u~c for 2 h. The reaction was diluted with saturated aqueous sodium hydrogen carbonate (1.5 L) and extracted with ethyl acetate (3 x I L). The organic layers were combined, dried with brine, anhydrous m~gn~ lm sulfate, filtered, and evaporated under reduced pressure to give a yellow oil which was dissolved in ethyl acetate (700 mL), cooled in an ice/water bath.
15 Hydrogen chloride gas was bubbled into the solution for 3 h. The reaction mixture was cullcelllldl~d under reduced pressure and the resulting foam was dissolved in ethyl acetate (1 L) and saturated aqueous sodium hydrogen carbonate (I L). The layers were separated and the aqueous layer was extracted with ethyl acetate again (2xl L). The 20 organic layers were combined, dried with brine, dnhy(huus m~gnPcillm sulfate, filtered, and evaporated under reduced pressure to give a white solid, which was chromatographed over silica (2.5 kg) with ethyl acetate.
The faster running diastereomer was recovered as a white solid (22.0 g, 72%). IH NMR, CDC13, o 9.02 (d, J=8.6 Hz, lH), 7.64-7.25 (m, 14H), 25 5-50 (d, J=8.6 Hz, lH), 4.54 (septet, J=7.0 Hz, lH), 3.70 (dd, J=3.9, 9.8 Hz, lH), 3.34 (dd, J= 3.9, 13.8 Hz, lH), 2.82 (dd, J=9.8, 13.8 Hz, lH), 1.51-1.40 (m, 5H), 1.27 (d, J=7.0 Hz, lH).
The absolute stereochemistry at C-3 of the b~n7o~li7~pine rulg was 30 determined to be "R" by single crystal X-Ray analysis The slower running diastereomer was recovered as a white solid (5.0 g, 16%). 1H NMR, CDC13, o 9.05 (d, J=8.5 Hz, lH), 7.63-7.20 (m, 14H), 5.48 (d, J=8.5 Hz~ lH), 4.56 (septet, J=7.0 Hz, IH), 3.74 (dd, J=4.3, 10.0 WO 96/05827 PCT/IJS95/lOSOI
21 959~73 Hz, lH), 3.37 (dd, J= 4.3, 13.8 Hz, lH), 2.68 (dd, J=10.0, 13.8 Hz, IH), 1.55-1.39 (m, SH), 1.29 (d, J=7.0 Hz, IH).
Step E: Preparation of 3R-(+) and 3S-(-) 3-Amino-2,3-dihydro-1-(2-propyl)-2-oxo-5 -phenyl- 1 H-benzo [e] [1,4]diazepine To a stirring solution of (2R)-2-amino-3-phenyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]
propionarnide (the faster running diastereomer from step D)(22 g, 49.9 mmol) in methylene chloride (100 mL) was added phenylisothiocyanate (7.17 mL~ 59.9 rnmol) and the resulting solution was stirred for 16 h.
The reaction mixture was cun.;ell~ d under reduced pressure to yield a yellowish oil which was cooled im an ice/water bath. Trifluoroacetic acid (40 mL, 500 rnmol) was added dropwise to the oil and the resulting solution was allowed to warm to ambient l~ elalu~ over 2.5 h. The reaction mixture was concentrated under reduced pressure to yield a yellowish oil which was chromatographed over silica (I kg) with 90:10:1:1 methylene chloride: methanol: acetic acid: water. The resulting white foam was crystallized from ethyl acetate/hexane to give The 3R-(+) enantiomer as a white solid (9.5 g, 65%). MP = 155 - 157~C;
2 IH NMR, CDC13, o 7.63-7.20 (m, 9H), 4.58 (septet, J=7.0 Hz, lH), 4.41 (s, IH), 2.43 (s, 2H), l.SO (d, J=7.0 Hz, 3H), 1.23 (d, J=7.0 Hz, 3H).
[a]D = +150~ (c=0.63; MeOH) The 3S-(-) en~nl~nmPr was prepared in the same fashion by starting with the slower running diastereomer from step D.
MP = 155 - 157~C;
IH NMR, CDC13, o 7.63-7.20 (m, 9H), 4.58 (septet, J=7.0 Hz, IH), 4.41 (s, IH), 2.43 (s, 2H), 1.50 (d, J=7.0 Hz, 3H), 1.23 (d, J=7.0 Hz, 3H).
[a]D = -159~ (c=0.83, MeOH) Step F: Preparation of (+)-3-(3,5-Dichloro)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]
~?~on7:~mide ~ W096/05827 . 2 1 9 5 9 7 3 PCT/US95/10501 To a stirring solution of (+)3R-3-ammo-2,3-dihydro-1-(2-~ propyl)-2-oxo-5-phenyl-lH-1,4-bPn7n~i,q.7epine (5.2 g, 17.7 mmol) in dimethylformamide (20 mL) was added EDC (4.08 g, 21.3 mmol), HOBT (2.87 g, 21.3 mmol) and 3,5-dichlorobenzoic acid (4.06 g, 213 mmol). This was stirred at ambient temperature for 2 h. The reaction was diluted with saturated aqueous sodium hydrogen carbonate (700 mL) and extracted with ethyl acetate (3 x 500 mL). The organic layers were combined, dried with brine, anhydrous m,qgT~ lm sulfate, filtered, and evaporated under reduced pressure to give a colorless oil which was chromatographed over silica with 10 to 30% ethyl acetate/hexane. The resulting foam was crystallized from ethyl acetate/hexane to give a white solid (6.7 g, 81 %). mp=141-142~C, [c~]D=+80.6~ (c=0.74; MeOH), I H NMR, CDC13, ~ 8.03 (d, J=7.8 Hz, lH), 7.80-7.20 (m, 12H), 5.61 (d, J=7.8 Hz, lH), 4.58 (septet, J=7.0 Hz, IH), 1.52 (d, J=7.0 Hz, 3H), 1.32 (d, J=7.0 Hz, 3H).
Anal. Calcd. for C25H2lN3o2cl2:
C, 63.89; H, 4.59; N, 8.94. Found: C, 63.87; H, 4.70; N, 8.88%.
The following examples were prepared by a procedure AIII;AIIY as describedforExample I step Ffrom eitherthe 3R-(+) or the 3S-(-) amine ~nq~ltinmf-r obtained in step E.
Example 2 (+)-3-Cyclohexyl-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~ ide WO 96/05827 2 ~ 9 5 9 7 3 PCT0595/lOSOI
H
mp=154-155~C
[a]D=+58.7~ (c=0.77; MeOH) lH NMR, CDC13, o 7.60-7.13 (m, 10H), 5.48 (d, J=8.3 Hz, lH), 4.53 (septet, J=6.9 Hz, lH), 2.40-2.34 (m, 2H), 1.80-1.43 (m, 10H), 1.39-1.10 (m, 7H), 1.01-0.92 (m, 2H).
Anal. Calcd. for C27H33N302:
N-2,3-DIHYDRO- 1 -(2-PROPYL)-2-OXO-5-PHENYL- 1 H- 1 ,4-BENZODL~ZEPINES
Arrhythmias often occur as complications to cardiac diseases such as myocardial infarction and heart failure. In a serious case, ~hyll~ ias give rise to ventricular fibrillation and can cause sudden death.
Though various antia"yll",-ic agents are now available on the market, agents which exhibit both satisfactory effects and high safety profiles have not been obtained. For example, antiarrythmic agents of Class I, according to the cl~c~ific~ion of Vaughan-Williams, which cause a selective inhibition of the m~ximllm velocity of the upstroke of the 15 action potential (Vmax) are in:~tleqll~t~ for preventing ventricular fibril-lation. In addition, they have problems regardmg safety, namely, they cause a depression of the myocardial contractility and have a tendency to induce arrythmias due to an inhibition of the impulse conduction. Beta-adrenoceptor blockers and calcium antagonists which belong to Class Il 2 o and IV respectively, have a defect in that their effects are either limited to a certain type of al,hy~ "ia or are contr~3in~ tPd because of their cardiac de~ sal,i properties in certain patients with cardiovascular disease. Their safety, however, is higher than that of the antiarrhythmic agents of Class 1.
Antiarrythmic agents of Class III are drugs which cause a selective prolongation of the duration of the action potential without a ~ignific~nt depression of the Vmax. Drugs in this class are limited.
Examples such as sotalol and arniodarone have been shown to possess Class III properties. Sotalol also possesses Class II effects which may 3 o cause cardiac depression and be contraindicated in certain susceptible patients. Also, amiodarone is severely limited by side effects. Drugs of this class are expected to be effective in preventing ventricular fibrilla-tions. Pure Class III agents, by definition, are not considered to cause myocardial depression or an induction of a"l,y~ "ias due to the W096/05827 2 1 959 73 PCT/US95/10501 ~
inhibition of the action potential conduction as seen with Class I
a--iial-l-yll.---ic agents.
SUMMARY OF TH~ INVl~NTION
This invention is concerned with novel compounds ;s~nl~d by structural formula I
~N ~ ~
~:N H (cH2)n ~. , I
where Rl is ~y or ~
X and Y are independently hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl;
nisO, l or2;and R2 is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy;
as the la~~lllal~s, mixtures of enantiomers, individual diastereomers or individual enantiomers, and ph~l " ,~. r~ll ically acceptable crystal forms, salts, or hydrates thereof, which are useful as antiarrhythmic agents.
The compounds of the present invention may have asymmetric centers and occur as r~r~rn:~Pc mixtures of enantiomers, individual diastereomers, or as individual enantiomers with all isomeric _ . . _ . . . . . _ . _ . . . . . _ .
~ WO 96/0582'1 2 ~ 9 5 9 7 3 PCT/US95/10501 forms being included in the present invention. The invention is also concerned with ph~rrn~entir~l formulations ~o~ )flsillg one of the novel compounds as an active ingredient.
The invention is also concerned with a method of treating 5 arrhythmia by the ad.~ ion of one of the novel compounds or formulation thereof to a patient in need of such treatment.
DETAILED DESCRIPTION OF THE INVENTION
The novel compounds of this invention have structural 10 formula ~N ~ ~
~-cN H (CH2)n where Rl is ~y or ~
X and Y are in~PpP.n~ ntly hydrogen, fluoro, chloro, b}omo, iodo, or trifluoromethyl;
30 nisO, I or2;and R2 is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy;
as the r~rl~m~t~s, mixtures of en~ntiomPrs, individual diastereomers or individual enantiomers, and pl-," " ,;~,,1 ically acceptable crystal forms, wos6/oss27 2~ 95~73 PCIIUS95110501 ~
salts, or hydrates thereof. These compounds include pharm~rent~ ly acceptable crystal forms and hydrates of the compounds of Formula 1, which are ~llialflly~ llic agents.
The compounds of the present invention may have 5 asymmetric centers and occur as racemates, mixtures of enantiomers, individual diastereomers, or as individual ~n~ntiomf rs with all isomeric forms being included in the present invention.
One preferred embodiment of the present invention is (+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~et:~mide ~~ CF
N_~O ~ ~ 3 ~GN H CF3 Another embodiment of the novel compounds of this invention is ~+)-3,5-Dichloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][I ,4]diazepin-3-yl]ltrn7~lmi~
~ O Cl N~ ~ /=<
~5 N) H
A second embodirnent of the novel compounds of this invention is (+)-3-Cyclohexyl-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l,4]diazepin-3-yl]~ d"a",ide ~ WO 96/0S827 2 1 9 5 9 7 3 PCT/U595/lOSOI
s ~$ 1, 10Still another embodiment of the novel compounds of this invention is (+)-2-(3,4-Dichlorophenyl)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][ I ,4]diazepin-3-yl]~ret~mi~
~0 ~ CI
Other examples of the cl ." ,l.""~c of this invention include:
(+)-2-(3,5-Dichlol~Jpllellyl)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1 H-benzo[e] [ I ,4]diazepin-3-yl]~ret?rni-iP
~ Cll N--~~ ~0'C I
3 o \~5N H
WO 96/05827 PCT/US95/10501 ~
(+)-3-(2,4-Dichlorophenyl)-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]lulù~Jdna~llide N H 1~ C I
(-)-3-(2,4-Dichlorophenyl)-N-[3S-2,3-dihydro- 1 -(2-propyl)-2-oxo-5 -phenyl-lH-benzo[e][1,4]diazepin-3-yl]l,-u~ ide ~$H
(-)-3-(3,4-Dichloro)-N-[3S-2,3-dihydro- 1 -(2-propyl)-2-oxû-5-phenyl- 1 H-benzo[e][ I ,4]diazepin-3-yl]bPn7~mi-1.o I~H J~
~ WO 96/05827 21 9 5 9 7 3 PCT0S95110501 (+)-2-Afi,qm,qnt,qn-l-yl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-~ lH-benzo[e][1,4]diazepin-3 yl1qretqmi(le ~N H
(+)-4-Cyclohexyl-N-[3R-2,3 -dihydro- I -(2-propyl)-2-oxo-S-phenyl- I H-benzo[e][l ,4]diazepin-3-yl]bntqnqmi(l-~
_~0 ~~0 (+)-A~qmqntqn- I -yl-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-25 IH-benZO[e][l,4]diaZepill-3-yl]CarbOXalllide 3 0 ~N H
WO 96/0582~ 2 1 ~ 5 9 7 3 PCT/US9~/10~01 (+)-2-[3,5-Bis(trifluoromethyl)phenyl] -N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]~et~mitl~
N H
(+)-2-(2,4-Dichlorophenyl)-N-[3R-2,3-dihydro-l -(2-propyl)-2-oxo-5-phenyl-lH-benzo~e][l ,4]diazepin-3-yl]acetamide ~lal N
(+)-3-Chloro-N-[3R-2,3 -dihydro- I -(2-propyl)-2-oxo-5-phenyl-1 H- 1,4-25 benzodiazepin-3-yl]b~on7~m~
~--~'n'HN)~CI
/CI\ .
~ WO 96/05827 . 2 1 9 5 9 7 3 PCT/US95/10501 (+)-4-Chloro-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH- 1,4-benzodiazepin-3-yl]benzamide .
~0 ~3 (+)-2-(3-Chlorophenyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1 ,4]diazepin-3-yl]~ret:~mi(lt~
~ ~0 ~
(+)-3-Bromo~-chloro-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]dia~epin-3-yl]ben7slmi~1~
~~ ~
W O 96/05827 2 1 q 5 q 7 3 PC~rAUS95/10501 3,4-Dichloro-N-[2,3-dihydro-1 -(2-propyl)-2-oxo-5-(2-fluorophenyl)-1 H-benzo[e][ I ,4~diazepin-3-yl]k~n7.~mide ~~ O
H
o ~F
(+)-3-Bromo-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l74]diazepin-3-yl]b n7.~mi~1~
N ~ Br 2 5 3-Cyclohexyl-N-L2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(2-fluorophenyl)- 1 H-benzo[e][1,4]diazepin-3-yl]p,~ all-ide 3 o ~5~N~O
g~F
~ W0 96/05827 . 2 l 9 5 9 7 3 PCr/USg5ll050l 3-(3,5-Dichloro)-N-[3S-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]ben7.~mi~
~ N H~
(+)-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl- I H- 1,4-b~n70~ 7.f~pin-3-yl]bl~n7.~mi,l,-~ N ~3 g~
(+)-2-(3-Trifluorome~ylphenyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-25 oxo-5-phenyl-lH-benzole][1,4]diazepin-3-yl]~e~lmi-~N H CF3 g~
WO 96/05827 2 1 9 5 9 7 3 PCT/US9511050~ ~
(+)-3,5-Bis(trifluoromethyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-S-phenyl- I H-benzo[e] [ I ,4]diazepin-3 -yl]bPn7.~mide N J~c F3 (+)-2-(2-Trifluoromethylphenyl)-N-[3R-2,3-dihydro- l -(2-propyl)-2-oxo-~-phenyl-lH-benzo[e][l~4]diazepin-3-yl]~ret~ dp N ~3 (+)-2-(4-TrifluululllelllyllJhenyl)-N-~3R-2,3-dihydro-1 -(2-propyl)-2-25 oxo-~-phenyl- 1 H-benzo~e]l I ,4]diazepin-3-yl]~et~mi,l.o ~ ~o ~ ~CF3 ~ WO 96/05827 2 1 9 5 9 7 3 PCT/US95110501 (+)-2-Phenyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[E] [ 1 ,4]diazepin-3-yl]acetamide (-)-2-(3,5-Dichlorophenyl)-N-[3S-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][ I ,4]diazepin-3-yl]acetarnide Cl ¢~=$ N ~ J~C I
~
(-)-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[3R-2,3-dihydro- 1 -(2-2s propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~,~et:~mitllo ~sN H OH CF3 ~ ,~
WO 96105827 2 1 9 5 9 7 3 PCTIUSgSlloSol (+)--2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[3R- I -(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-lH-ben~o[e][l ,4]diazepin-3-yl]:~ret:~mifie .
¢~N O H CF3 ~
(+)-3-Cyclohexyl-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(4-fluoprophenyl)-lH-benzo[e][1,4]diazepin-3-yl]l~lup~lalllide < ~N'~I--'O
(+)-3 ,S-Dichloro-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(4-fluorophenyl)-25 lH-benzo[e][1,4]diazepin-3-yl]h~n7~mi~
~, wo 96/0s827 2 1 9 5 9 7 3 PcTrusg5rlo501 ~ O
~ Cl F
A novel process for preparing the compounds of this invention is srhPm:~rir~lly exemplified below im scheme, and these steps are well known in the art and/or described in the Examples that follow.
W096/05827 . ~1 95~73 PCWS95110501 Scheme 1 HN~O iPr-l ~N~
~ N Cs2CO3 ~ N
~,N KHMDS
i o ~.~N~ N~
~J~ NH2 P(Ph)3 ~/ ~N3 ~N . \~N
\ D-Boc-Phe-OH, EDC, HOBT
~N
¢~N H NHBoc HCI (9) ~ WO 96/05827 2 1 9 5 9 7 3 PCT/US95/lOSOI
Scheme 1 cont'd.
¢~H ~'z ¦ Separate Diaste~omers ~5~NH-D-Phe-H 1~ IH-D-Phe-H
~ ' 1 . 1) PhNCS
~ 2) TFA _~
NH2 [~ ~ NH2 ~N ~N
R(CH2)nCOCI or R(CH2)nCO2H, EDC, HOBT , /
N~ (CH2)n~R ¢~ N~ (CH2)n-R
R = O ; ~ X X~Y= H, Cl, CF3, Br WO 96/05827 2 1 ~ 5 9 7 3 PCT/US95110501 The novel compounds of the present invention have the pharmacological properties required for antiarrhythmic agents of C~lass III, namely they demonstrate prolongation of QTc-interval, and dose dependent increases im ventricular refractoriness. This is accom-plished without effecting heart rate, mean arterial pressure and PR and QRS intervals. Modest increases in LV+dPldt (left ventricular change im pressure with time) is observed. Further, these compounds suppress the induction of PVS (Programmed Ventricular Stimulation) induced o ventricular tachyarrhythmias.
These compounds are effective in treating and preventing all types of a-lllyll~--ias including ventricular and atrial (supraventricular) arrhythmias. The compounds of the present invention are especially useful to control reentrant arrhythmias and prevent sudden death due to the ventricular fihrill~tinn These compounds are also effective in treating and preventing impaired cardiac pump functions.
In the novel method of this invention of treating arrhythmia, one of the compounds or pl~ c~ icsllly acceptable salt thereof, is ~.l,,,;,,i~l~,c~d in an amount ranging from about .0001 to about 10 mg per kg of body weight per day, preferably from about .0001 to about 2 mg per kg of body weight per day, and more preferably by iu~ wus delivery of from about 0.0003 to about 0.3 mg per kg of body weight per day, or when given orally from about 0.03 to about I mg per kg of body weight per day, in a single dose or in 2 to 4 divided doses.
These compounds, orpl~ ",;~.~elll;r~lly acceptable salts thereof, in the described dosages, are ~ cd orally, iullldlue,ilu"e-ally, ,suh.~ l.Pously, intr~mll~clll~rly, transdermally, sublingually or intravenously. They are preferably ~lmini~ti~red intravenously or orally, for example in the form of tablets, troches, capsules, elixirs, ~u~)en~iùns, 3 0 ~mnl~ion~ syrups, wafers, chewing gum, or the like prepared by art recognized procedures. The amount of active compound in such thera-peutically useful compositions or preparations is such that a suitable dosage will be obtained.
~ WO 96/05827 2 1 9 5 ~ 7 3 PCT/US95110501 These compounds can be ~mini~t~red as the sole active ingredient or in combination with other antiarrhythmic agents or other ~ cardiovascular agents, such as Class 1, Class Il or Class IV antiarrhythmic agents, vasodilators, angiotensin converting enzyme inhibitors, 5 angiotensin II antagonists, diuretics or digitalis.
These compoumds can be :~(iminist~red as a method of treat-ing arrhythmia and impaired cardiac pump functions in conjunction with defibrillators, including implantable defibrillators. These compounds reduce the frequency of defibrillator firing.
By Class I ~l~iallhyllllllic agents is meant those agents which provide for sodium channel blockade, mcluding those compounds which exert a ~llellJl,ldlle stabilizing effect. Exemplary of this class of compounds are qlliniriin~ l,lu':Ai~ ie, disopyramide, lidocane, tocainide, flt-r~ini(1~- and plulJdrt;llolle. By Class Il ~lliallhyllllllic compounds is meant those agents which block symp~thf~ti~ activity.
Exemplary of this class of compounds are propranolol and acebutolol.
By Class m antiarrhythmic agents is meant those compounds which prolong the effective refractory period without altering the resting membrane potential or rate of depolarization. In addition to the novel 20 compounds of this invention, compounds such as amiodarone, bretylium and sotalol are considered to be in this class. Class IV allliallhyllllllic agents are effective in calcium channel blockade. Exemplary of this class of compounds are diltiazem and verapamil. Further definition of these classes can be found in Pharma Projects, section CIB, May 1993, which 25 is hereby incul~,uldl~d by reference.
Exemplary of vasodilators are compounds such as papaverine and isosorbide dinitrat. Examples of :~ngiot~n~in converting enzyme inhibitors include enalapril, lisinopril and captopril. Examples of diuretics include hydrochlorothiazide and acetazolamide. The pharma-3 0 ceutical agents listed herein are examples and do not represent a completelisting of the many compounds in these classes which are contemplated by this invention.
The activity of the compounds described herein as antiarrhythmic agents is measured by their ability to block the IKS
27 95~3 and IKr currents as .1~ t~rminf~d by the following test protocol.
Outward potassium currents are measured in single guinea pig ventricular myocytes using a whole-cell voltage clamp technique described in detail elsewhere (~qn~in~tti and Jurkiewicz, 1990, Two 5 components of cardiac delayed rectifier K+ current: differential se~ ivily to block by Class m ~lliallhy~ llic agents. J. Gen Physiol.
96: 195-215). Myocytes are isolated by enzymatic (collagenase and protease) digestion of T ~ng~ndorf perfused hearts. Single cells are then voltage clamped using I mm square-bore pipettes filled with 0.5 M
gluconate, 25 mM KCI, 5 mM K(2)ATP. Cells are bathed in a solution containing,inmM: 132NaCI,4KCI, 1.2MgC12, 10HEPES, 10glucose:
pH 7.2, temp. 35~C.
Each cell is m~int~inPd at a holding potential of -50 mV.
Test depolarizations are applied as voltage rarnps from -85 to -50 mV, and as steps to -10 mV (0.5 s) and +50 mV (1.0 s). IKI is measured as peak outward current during the voltage ramp. IKr is measured as tail currents upon repolarization from -10 mV to -50 mV. IKS is measured as time-dependent current during the pulse to +50 mV. Currents are measured during control, then after exposure to drug at two different 2 o ~nn(~ntrzltion~
Employing this test the compounds described herein have an ICso of less than 100 nM as IKS blockers. The comounds of this invention are at least 10 times more potent in the blockade of IKS than the blockade of IKr-2s Fxample 1 (+)-3,5-Dichloro-N- [3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl - 1 H-benzo[e][l ,4]diazepin-3-y]]bPn7~mi~
~ WO 96105827 PCTIUS95110501 2l ~5973 ~ N H ~
~ Cl Step A: Preparation of 2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-o lH-benzo[e][1,4]diazepine A solution of S-phenyl-l ,4-ben70~ 7f pine-2-one (J. Org.
Che~r., 1962, 27, 3788)(50 g, 0.21 lmole) in DMF (100 mL) was treated with Cesium carbonate (82.8 g, 0.254mole) and 2-iodup.upd.lf (43.2 g, 5 0.254 mole). The mixture was stirred at room L~ alul~ for five hours.
The reaction mixture was then poured into water (2L) and extracted with ethyl acetate (3 X IL). The combined ethyl acetate fractions were dried over anhydrous m~gnf ~inm sulfate, filtered and concentrated at reduced pressure. The residue was crystallized from ethyl ether to give 45 g (77 20 %) of the product. MP = 153 - 155~C
IH NMR (CDC13) o 7.65-7.6(m, 2H), 7.60-7.35 (m, SH), 7.35-7.20 (m, 2H),4.72(d, J = 10 Hz, lH), 4.58 (hep, J = 6.8 Hz, lH), 3.75 (d,J=lOHz, lH), 1.5(d,J=6.8Hz,3H),1.2(d,J=6.8Hz,3H).
25 Step B: Preparation of 3-Azido-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl- 1 H-benzo[e] [1,4]diazepine To a solution of 2,3-dihydro-1-(2,propyl)-2-oxo-5-phenyl-~ 1 H- 1,4-benzodiazepine (50 g, 0.179 mole) in THF (1200 mL) at -70~C
30 was added a solution of potassium bis(trimethylsilyl) amide in toluene (400 mL of a 0.5 N solution, 0.20 mole). The deep orange solution was then treated with a solution of lliisul,lu~,yll,r"~f .~f~,llfonyl azide (61.1 g,0.197 mole) in THF (200 mL). The reaction was stirred at -70~C for 10 minutes and then treated with acetic acid (4 mL in 20 mL of THF) and WO 96/05827 2 1 9 ~ 9 7 3 PCT/US95110501 warmed to room le-l-peldlul~ over one hour. The reaction mixture was then poured into water (1.5 L) and extracted with ethyl acetate (3 X 500 mL) The combined ethyl acetate fractions were washed with a solution of sodium bicarbonate (300 mL), then water (2 X 500 mL), and then brine 5 (500 mL). The ethyl acetate solution was then dried over anhydrous m~gn~sillm sulfate, filtered and concentrated at reduced pressure. The residue was crystallized from ethyl ether to give 48 g (84 ~o) of the product. MP= 178 - 179~C;
H NMR (CDCI3) o 7.75-7.65(m, 2H), 7.60-7.20 (m, 7H), 4.58 (hep, o J = 6.8 Hz, IH),4.45(s, lH), 1.51 (d, J = 6.8 Hz, 3H), 1.26 (d, J = 6.8 Hz, 3H)-~: Preparation of racemic 3-Amino-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepine To a solution of 3-azido-2,3-dihydro-1-(2,propyl)-2-oxo-5-phenyl-lH-1,4-benzodiazepine (48 g, 0.15 mole) in THF (500 mL) at room l~ ulc; was added water (40 mL) and triphenyl phosphine (90 g, 0.343 mole). The reaction was stirred at room Lt;lll~ iUI~ for 24 hours 20 and conr~nt-~rl-d at reduced pressure. The residue was partitioned between lN H~l (1.5 L) and ether (500 mL). The ether layer was discarded and the aqueous phase was extracted with ethyl acetate ( I X
100 mL) which was also discarded. The aqueous phase was basified to pH 8 by careful addition of 6 N sodium hydroxide solution and extracted 25 with ethyl acetate (3 X 500 mL). The combined ethyl acetate phases were dried over anhydrous m~nf~sillm sulfate, filtered, and cu~). r~ ed at reduced pressure. The residue was crystallized from ethyl ether to give 41.7 g (94 %) of the product. MP = 130-135~C;
lH NMR (CDC13) ~ 7.75-7.65 (m, 2H), 7.60-7.20 (m, 7H), 4.65 (hep, 30 J = 6.8 Hz, lH),4.43 (s~ lH), 2.5 (br s, 2H,-NH2),1.51 (d, J = 6.8 Hz, 3H), 1.26(d,J=6.8Hz,3H).
_ WO 96/05827 PCT/US95/10501 2l 95973 ~ ~ Preparation of (2R)-2-Amino-3-phenyl-N-[2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][1,4]diazepin-3-yl]
propionamide To a stirring solution of ( )-3-amino-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-1,4-b~n7O~ 7l~pine (40.8 g, 139 mmol) in dimethylformamide (140 mL) was added EDC (32.0 g, 167 mmol), HOBT (22.6 g, 167 mmol) and N-BOC-D-phenylalanine (44.3 g, 167 mmol). This was stirred at ambient l~ eld~u~c for 2 h. The reaction was diluted with saturated aqueous sodium hydrogen carbonate (1.5 L) and extracted with ethyl acetate (3 x I L). The organic layers were combined, dried with brine, anhydrous m~gn~ lm sulfate, filtered, and evaporated under reduced pressure to give a yellow oil which was dissolved in ethyl acetate (700 mL), cooled in an ice/water bath.
15 Hydrogen chloride gas was bubbled into the solution for 3 h. The reaction mixture was cullcelllldl~d under reduced pressure and the resulting foam was dissolved in ethyl acetate (1 L) and saturated aqueous sodium hydrogen carbonate (I L). The layers were separated and the aqueous layer was extracted with ethyl acetate again (2xl L). The 20 organic layers were combined, dried with brine, dnhy(huus m~gnPcillm sulfate, filtered, and evaporated under reduced pressure to give a white solid, which was chromatographed over silica (2.5 kg) with ethyl acetate.
The faster running diastereomer was recovered as a white solid (22.0 g, 72%). IH NMR, CDC13, o 9.02 (d, J=8.6 Hz, lH), 7.64-7.25 (m, 14H), 25 5-50 (d, J=8.6 Hz, lH), 4.54 (septet, J=7.0 Hz, lH), 3.70 (dd, J=3.9, 9.8 Hz, lH), 3.34 (dd, J= 3.9, 13.8 Hz, lH), 2.82 (dd, J=9.8, 13.8 Hz, lH), 1.51-1.40 (m, 5H), 1.27 (d, J=7.0 Hz, lH).
The absolute stereochemistry at C-3 of the b~n7o~li7~pine rulg was 30 determined to be "R" by single crystal X-Ray analysis The slower running diastereomer was recovered as a white solid (5.0 g, 16%). 1H NMR, CDC13, o 9.05 (d, J=8.5 Hz, lH), 7.63-7.20 (m, 14H), 5.48 (d, J=8.5 Hz~ lH), 4.56 (septet, J=7.0 Hz, IH), 3.74 (dd, J=4.3, 10.0 WO 96/05827 PCT/IJS95/lOSOI
21 959~73 Hz, lH), 3.37 (dd, J= 4.3, 13.8 Hz, lH), 2.68 (dd, J=10.0, 13.8 Hz, IH), 1.55-1.39 (m, SH), 1.29 (d, J=7.0 Hz, IH).
Step E: Preparation of 3R-(+) and 3S-(-) 3-Amino-2,3-dihydro-1-(2-propyl)-2-oxo-5 -phenyl- 1 H-benzo [e] [1,4]diazepine To a stirring solution of (2R)-2-amino-3-phenyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]
propionarnide (the faster running diastereomer from step D)(22 g, 49.9 mmol) in methylene chloride (100 mL) was added phenylisothiocyanate (7.17 mL~ 59.9 rnmol) and the resulting solution was stirred for 16 h.
The reaction mixture was cun.;ell~ d under reduced pressure to yield a yellowish oil which was cooled im an ice/water bath. Trifluoroacetic acid (40 mL, 500 rnmol) was added dropwise to the oil and the resulting solution was allowed to warm to ambient l~ elalu~ over 2.5 h. The reaction mixture was concentrated under reduced pressure to yield a yellowish oil which was chromatographed over silica (I kg) with 90:10:1:1 methylene chloride: methanol: acetic acid: water. The resulting white foam was crystallized from ethyl acetate/hexane to give The 3R-(+) enantiomer as a white solid (9.5 g, 65%). MP = 155 - 157~C;
2 IH NMR, CDC13, o 7.63-7.20 (m, 9H), 4.58 (septet, J=7.0 Hz, lH), 4.41 (s, IH), 2.43 (s, 2H), l.SO (d, J=7.0 Hz, 3H), 1.23 (d, J=7.0 Hz, 3H).
[a]D = +150~ (c=0.63; MeOH) The 3S-(-) en~nl~nmPr was prepared in the same fashion by starting with the slower running diastereomer from step D.
MP = 155 - 157~C;
IH NMR, CDC13, o 7.63-7.20 (m, 9H), 4.58 (septet, J=7.0 Hz, IH), 4.41 (s, IH), 2.43 (s, 2H), 1.50 (d, J=7.0 Hz, 3H), 1.23 (d, J=7.0 Hz, 3H).
[a]D = -159~ (c=0.83, MeOH) Step F: Preparation of (+)-3-(3,5-Dichloro)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]
~?~on7:~mide ~ W096/05827 . 2 1 9 5 9 7 3 PCT/US95/10501 To a stirring solution of (+)3R-3-ammo-2,3-dihydro-1-(2-~ propyl)-2-oxo-5-phenyl-lH-1,4-bPn7n~i,q.7epine (5.2 g, 17.7 mmol) in dimethylformamide (20 mL) was added EDC (4.08 g, 21.3 mmol), HOBT (2.87 g, 21.3 mmol) and 3,5-dichlorobenzoic acid (4.06 g, 213 mmol). This was stirred at ambient temperature for 2 h. The reaction was diluted with saturated aqueous sodium hydrogen carbonate (700 mL) and extracted with ethyl acetate (3 x 500 mL). The organic layers were combined, dried with brine, anhydrous m,qgT~ lm sulfate, filtered, and evaporated under reduced pressure to give a colorless oil which was chromatographed over silica with 10 to 30% ethyl acetate/hexane. The resulting foam was crystallized from ethyl acetate/hexane to give a white solid (6.7 g, 81 %). mp=141-142~C, [c~]D=+80.6~ (c=0.74; MeOH), I H NMR, CDC13, ~ 8.03 (d, J=7.8 Hz, lH), 7.80-7.20 (m, 12H), 5.61 (d, J=7.8 Hz, lH), 4.58 (septet, J=7.0 Hz, IH), 1.52 (d, J=7.0 Hz, 3H), 1.32 (d, J=7.0 Hz, 3H).
Anal. Calcd. for C25H2lN3o2cl2:
C, 63.89; H, 4.59; N, 8.94. Found: C, 63.87; H, 4.70; N, 8.88%.
The following examples were prepared by a procedure AIII;AIIY as describedforExample I step Ffrom eitherthe 3R-(+) or the 3S-(-) amine ~nq~ltinmf-r obtained in step E.
Example 2 (+)-3-Cyclohexyl-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~ ide WO 96/05827 2 ~ 9 5 9 7 3 PCT0595/lOSOI
H
mp=154-155~C
[a]D=+58.7~ (c=0.77; MeOH) lH NMR, CDC13, o 7.60-7.13 (m, 10H), 5.48 (d, J=8.3 Hz, lH), 4.53 (septet, J=6.9 Hz, lH), 2.40-2.34 (m, 2H), 1.80-1.43 (m, 10H), 1.39-1.10 (m, 7H), 1.01-0.92 (m, 2H).
Anal. Calcd. for C27H33N302:
5 C,75.14;H,7.71;N,9.74.Found:C,75.28;H,7.71;N,9.86Yo.
l~xarnple 3 (+)-2-(3,4-Dichlorophenyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-20 phenyl-lH-benzo[e][1,4]diazepin-3-yl];~et:~mi(l~
l~N H
.
30 mp=l7l-l72t~c [a]D =+37.0~ (c=0.61; MeOH) lH NMR, CDC13, o 7.59-7.19 (m, 10H), 5.44 (d, J=8.3 Hz, lH), 4.54 (septet, J=6.9 Hz, IH), 3.54 (s, 2H), 1.49 (d, J=6.9 Hz, 3H), 1.25 (d, J=6.9 Hz, 3H).
- =
WO 96/05827 . PCT/US95J10501 ~ 21 9~7~
- Anal. Calcd. for C26H23N3o2cl2: -C, 65.01; H, 4.83; N, 8.75. Found: C, 65.00; H, 4.89; N, 8.71%.
Example 4 (+)-2-(3,5-Dichlorophenyl)-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl- I H-benzo[e] [1,4]diazepin-3 -yl]~ e~midP
N~C
mp=90-96~C
[a]D = +42.7~ (c=0.71; MeOH) lH NMR, CDC13, ~ 7.59-7.19 (m, 10H), 5.44 (d, J=8.3 Hz, IH), 20 4 54 (septet, J=6.9 Hz, lH), 3.54 (s, 2H), 1.49 (d, J=6.9 Hz, 3H), 1.25 (d, J=6.9 Hz, 3H).
Anal. Calcd. for C26H23N3O2C12-0.20 H20:
C, 64.52; H, 4.87; N, 8.68. Found: C, 64.55; H, 5.00; N, 8.54~o.
Fx~ ?le5 (+)-3-(2,4-Dichlorophenyl)-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]~..,pdlldlllide WO 96/05827 . 2 ~ 9 5 9 7 3 PCTNS95/10501 ~
N Y ~
¢~cN H Cl 10 m.p. 138-139 ~C, [a]D = +70.9" (c=0.79; MeOH).
Anal. Calcd. for C27H25N302C12:
C,65.59;H,5.1;N,8.5.Found:C,65.21;H,5.1;N,8.6%.
Examyle 6 (-)-3-(2,4-Dichlorophenyl)-N-[3S-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~ an~llide -~ , m.p. 142-143 ~C, [a]D = -66.3~ (c=0.64; MeOH).
Anal. Calcd. for C27H25N3o2cl2.:
C, 65.59; H, 5.1; N, 8.5. Found: C, 65.51; H, 5.04; N, 8.65%.
F~mrle 7 (-)-3-(3,4-Dichloro)-N-[3S-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl- 1 H-benzo[e][1,4]diazepin-3-yl]bPn7~mi~
~ WO 96/05827 . PCT/US95/10501 -- 21 9~9~3 H J~
10 m.p. 143-144 ~C, [a]D = -72.2~ (c=0.45; MeOH).
Anal. Calcd. for C25H21N3O2C12-0.55 mol cyclohexane:
C, 66.3; H, 5.43; N, 8.2. Found: C, 66.31; H, 5.49; N, 8.19%.
Example 8 (+)-2-(A-i~m:lnt~n-1 -yl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]~ret:~mi~1r ¢~, m.p. 176-177 ~C, [oc]D = +63.5~ (c=0.51; MeOH).
Anal. Calcd. for C30H3sN3o2:
C, 76.73; H, 7.51; N, 8.95. Found: C, 76.39; H, 7.46; N, 8.86~o.
Fx~mple 9 (+)4-Cyclohexyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]bnt~n~mi(li~
WO 96/05827 . PCTIUS95/10501 2 ~ 95973 s ~ H
m.p. foam ~C, [~c]D = +59.1 ~ (c=0.43; MeOH)..
Anal. Calcd. for C2gH35N3O2-0.20 mol H20:
C, 74.87; H, 7.94, N, 9.35. Found: C? 74.92; H, 7.88; N, 9.35%.
Example 10 (+)-~lqm:~nt~n- I -yl-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]carboxamide N
N
m.p. 206-207 ~C, [oc]D = +38.5~ (c=0.52; MeOH).
Anal. Calcd. for C29H33N302-0.30 mol H20:
C, 75.56; H, 7.35; N, 9.11. Found: C, 75.62; H, 7.33; N, 8.91%.
Example 11 (+)-2-[3,5-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][ l ,4]diazepin-3-yl]~et~mi(lP
~ WO 96/05827 . 2 l 9 5 9 7 3 PCTrusg5rl0sol --~ C F3 ~5N H CF3 m.p. 152-153 ~C, [a]D = +37.5~ (c=0.65; MeOH).
Anal. Calcd. for C28H23N3o2F6:
C, 61.43; H, 4.23; N, 7.67. Found: C, 61.47; H, 4.22; N, 7.7~O.
Fx~n~le 12 (+)-2-(2,4-Dichlol uphcllyl)-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yllf~.ç~t~mide 2 0 ~ N
m.p. 78-84 ~C, [a]D = +26.3~ (c=0.67; MeOH).
Anal. Calcd. for C26H23N3O2C12-0.20 mol cyclohexane:
C, 65.7; H, 5.15; N, 8.45. Found: C, 65.53; H, 5.25; N, 8.35%.
- Example 13 (+)-3-Chloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][1,4]diazepin-3-yl]kPn7~mi~P
WO 96/05827 ' PCT/USgS/10501 21 95~73 N~CI
m.p. 79-86 ~C, [oc]D = +50.5~ (c=0.55; MeOH).
Anal. Calcd. for C25H22N3O2CI-0.35 mole cyclohexane:
C, 70.55; H, 5.72; N, 9.11. Found: C, 70.63; H, 5.79; N, 9.18%.
Fx~mRle 14 (+)-4-Chloro-N-[3R-2,3 -dihydro-l -(2-propyl)-2-oxo-5-phenyl- I H-benzo[e][l ,4]diazepin-3-yllbPn7s,mi~
-;~
m.p. 168-169 ~C, [a]D = +79.7" (c=0.96; MeOH).
Anal. Calcd. for C25H22N3O2CI.:
C, 69.52; H, 5.13; N, 9.73. Found: C, 69.75; H, 5.19; N, 9.9%.
Fx:~m,l?le 15 (+)-2-(3-Chlo~ h~llyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-ben_o[e][l,4]diazepin-3-yl]~ çr~mi-lP
~ WO 961058:~7 PCTIUS95/10501 ~N H
m-p- 137-139~C, [a]D= +44.2~ (c=0.60; MeOH).
Anal. Calcd. for C26H24N302CI.:
C, 70.03; H, 5.42; N, 9.42. Found: C. 70.23; H, 5.43; N, 9.45%.
Fx~mQle 16 (+)-3-Bromo-4-chloro-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]benzamide ~ N~[~Br ~
m.p. 173-175 ~C, [a]D = +58.6~ ~c=0.36; MeOH).
Anal. Calcd. for C25H20N3o2Brcl-o.4o mol H20:
C, 58.08; H, 4.06; N, 8.13. Found: C, 58.1; H, 4.14; N, 8.11%.
Example 17 (+)-3-Bromo-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl- 1 H -benzo[e][1 ,4]diazepin-3-yl]hen7:~,mi~P
N~Br m.p. 78-85 ~C, [a]D = +50.4~ (c=0.76; MeOH).
Anal. Calcd. for C25H22N302Br 0.85 mol H20 0.30 mol cy~lnh!~x~n~:
C, 62.27; H, 5.32; N, 8.13. Found: C, 62.27; H, 5.16; N, 8.03%.
Example 18 (-)-3,5-Dichloro-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]b.on7~mi(1~o ~ H~
Cl m.p. 140-141 ~C, [a]D = -83.7~ (c=0.52; MeOH).
Anal. Calcd. for C25H2lN3o2cl2-C, 64.39; H, 4.54; N, 9.01. Found: C, 64.36; H, 4.76; N, 8.62%.
Example 19 (+)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]ben7~mi~1to ~ WO 96/05827 . PCT/US9S/10501 21 95973 ~
m.p. 216-219 ~C, [a]D +53.9~ (c=0.36; CHC13).
Anal. Calcd. for C25H23N3o2:
C, 75.55; H, 5.83; N, 10.57. Found: C, 75.9; H, 5.87; N, 10.69%.
Example 20 (+)-2-(3-Trifluoromethylphenyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]sl~ et:lmi(le -20 ¢~~ ~--~'CF3 [a]D+35.9~(c--0.41; MeOH).
Anal. Calcd. for C27H24N3o2F3:
C, 67.63; H, 5.05; N, 8.76. Found: C, 67.96; H, 5.27; N, 8.37%.
Fx:~ml?le 21 (+)-3,5-Bis(trifluoromethyl) -N- [3R-2,3 -dihydro- I -(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]bPn7~mi(ie W096/05827 . 2195973 PCI/US95110501 ~
N ~c F3 10 m.p. 198-199 ~C, [a]D +39.2~ (c=0.53; MeOH).
Anal. Calcd. for C27H21N3O2F6-0.40 mol EtOAc:
C, 60.4; H, 4.29; N, 7.39. Found: C, 60.4; H, 4.28; N, 7.42%.
Example 22 (+)-2-(2-Trifluorornethylphenyl)-N-[3R-2.3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]S~et:lmi~l~
-~sN H CF3 m.p. 160-162 ~C, [oc]D +32.3~ (c=0.39; MeOH).
Anal. Calcd. for C27H24N3o2F3:
C, 67.63; H, 5.05; N, 8.76. Found: C, 67.58; H, 5.1; N, 8.85%.
Example 23 (+)-2-(4-Tlinuululll~ ylluh~;llyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~ref~mi~l~
~ WO 96105827 . PCT/US95/10501 s ~ N ~C F3 m.p. 227-228 ~C, [a]D +38.0~ (c=0.30; MeOH).
Anal. Calcd. for C27H24N3o2F3:
C, 67.63; H, 5.05; N, 8.76. Found: C, 67.93; H, 5.06; N, 8.98%.
lS Example 24 (+)-2-Phenyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]~ret~mi~l.q ~ N~3 ~_Y
m.p. 154-156 ~C, [a]d +40.3~ (c=0.38; MeOH).
Anal. Calcd. for C26H25N3O2-0.45 mol H20:
30 C, 74.42; H, 6.22; N, 10.01. Found: C, 74.45; H, 6; N, 9.96%.
WO 96/05827 . PCT/US95/10501 Fx;~rnple 25 (-)-2-(3,5-Dichlorophenyl)-N-[3S-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzoLe][1,4]diazepin-3-yl]acetamide ~ Cl ~ H
~
m.p. foam ~C, [a]D = -39.1~ (c=0.46; MeOH).
Anal. Calcd. for C26H23N3o2cl2:
C, 65.01; H, 4.83; N, 8.75. Found: C, 64.69; H, 4.85; N, 8.559'o.
Fx~ rle 26 20 (-)-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[1 -(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l ,4]diazepin-3-yl]~ret~mirl~
~--~'~ N~CF3 m.p. 195-6 ~C, [a]D = -33~ (c=0.49; MeOH).
Anal. Calcd. for C27H24N303F3:
C, 65.45; H, 4.88; N, 8.48. Found: C, 65.19; H, 4.83; N, 8.35%.
~ WO 96105827 2 1 9 5 9 7 3 PCT/US95~10501 Example 27 (+)-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[1 -(2-propyl)-2-oxo-S-phenyl-2,3-dihydro-lH-benzoLe][ l ,4]diazepin-3-yl]~et~mi~
~~ ~CF3 m.p. 227-8 ~C, [oc]D = +53~ (c=0.89; MeOH).
Anal. Calcd. for C27H24N303F3:
C, 65.45; H, 4.88; N, 8.48. Found: C, 65.26; H, 4.82; N, 8.55%.
F~lmrlç 28 20 (+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][l ,4]diazepim-3-yl]~re~:~mi~
/
~N H ~F
~ ' W096/05827 2 ~ 9 5 9 73 PCTIUS95/10501 ~
Step A. 2,4-Bis(trifluoromethyl)benzonitrile To a stirring biphasic mixture of 100mL ethanol and 250mL of pho~rh~t~
buffer (Ig of NaH2PO4-H2O per 5 mL H2O adjusted to pH=7.0 with 50%
NaOH) and NaCN (81.3mmol,4.0g) heated to 60~C was added 2,4-bis(trifluoromethyl) benzyl bromide (32.5rnmol,10g) in 50mL EtOH
dropwise over 30min. The reaction was heated at 60~C for 24h. The reaction was then evaporated under reduced pressure. The remaining aqueous was extracted with 2xl50mL EtOAc. The organic layers were combined, dried with brine and Na2SO4. The organic phase was evaporated under reduced pressure and the residue chromatographed over silica eluting with 10% EtOAc:Hexanes. The pure fractions were collected and evaporated to give 7.0g of a pale yellow oil, 85.1 % NMR
H (CDCI3) o 8.0-7.85 (m,3H), 4.03 (s,2H) Step B. 2,4-Bis(trifluoromethyl)phenyl acetic acid 2,4-Bis(trifluolu~ Ll.yl)benzonitrile (41.5mmol,10.51g) was taken up in 100mL acetic acid, 50mL conc. H2SO4, and 20mL water. This was heated to 120~Cfor 3h. The reaction was then diluted with IL ice water, and extracted with 2x300mL ethyl acetate. The ct-mhin~d organics were washed with 2x200mL water, dried with brine and Na2SO4, and evaporated under reduoed pressure. The residue was taken up in a minimnm of diethyl ether and crystallized by adding sufficient hexane to precipatate the product. The solid was collected to give 7.74g of 2,4-bis(trifluoromethyl) phenyl acetic acid as white crystals, 68.5%.NMR IH
(CDCI3) ~ 7.93 ~s,lH), 7.80 (d, J=7.9Hz,lH), 7.55 (d, J=7.9Hz,lH), 3.94 (s,2H).
Step C: (+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-I -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl] ~ oet~mi(l~
The 2,4-Bis-(trifluoromethyl) phenyl acetic acid obtained in step B
Wo 96/05827 . PCI/US95/10501 ~ was coupled with 3R-3-Amino-2,3-dihydro- 1- (2-propyl)-2-oxo-5-phenyl-lH-benzo[e][ 1 ,4]diazepine from step E example I by a procedure suh~t~nti~lly as desribed for step F example I to give (+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-5 phenyl-lH-benzo[e][1,4]diazepin-3-yl]-:~ret~,mi~P
m.p. 134-136 ~C, [a]D = +22~ (c=0.39; MeOH).
Anal. Calcd. for C28H23N3o2F3:
C,61.43;H,4.23;N,7.67.Found:C,61.61;H,4.24;N,7.75%.
The following examples were prepared by procedures ~ub~ lially as described in example I except sl-hstihltin~ the ~ -vpri~-te fluoro suh~titllt~d aminobenzophenone in step A.
Example 29 (+)-3-Cyclohexyl-N-[2,3-dihydrol -(2-propyl)-2-oxo-5-(4-fluoprophenyl)-lH-benzo[e][l,4]diazepim-3-yl]~"v~u~ lide ~
F
mp=179-181~C
[a]D=+45.1~ (c=0.55; MeOH) Anal. Calcd. for C27H32FN302:
C, 72.14; H, 7.17; N, 9.35. Found: C, 71.98; H, 7.10; N, 9.43%.
WO 96/05827 2 ~ 9 5 9 7 3 PCTIUS95/10501 ~
Example 30 (+)-3-S-Dichloro-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(4-fluorophenyl)-I H-benzo[e] [ I ,4]diazepin-3-yl]benzamide o ~ Cl m.p. 174-176 ~C, [a]D +53.9~ (c=0.36; CHC13).
Anal. Calcd. for C25H2ocl2FN3o2:
C, 61.54; H, 4.21; N, 8.61. Found: C, 61.54; H, 4.22; N, 8.72 Example 31 3-Cyclohexyl -N-r2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(2-fluorophenyl)- I H -benzo[e] [ l ,4]diazepin-3-yl]~ ,pallal-lide ~~ O
25 ~ Jl o /~F
m.p. 165-167 ~C.
Anal. Calcd. for C27H32N302F:
C,72.14;H,7.17;N,9.35.Found:C,71.71;H,7.11;N,9.33%.
~59;,73 ~xample 32 3,4-Dichloro-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(2-fluorophenyl)- I H-benzo[e][l ,4]diazepin-3-yl]b.on7~mi~1e '~ J~c F
m.p. l 88-189 ~C.
15 Anal. Calcd. for C25H2oN3o2cl2F~:
C,61.99; H,4.16; N, 8.68. Found: C, 61.7; H,4.22; N,8.59%.
l~xarnple 3 (+)-2-(3,4-Dichlorophenyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-20 phenyl-lH-benzo[e][1,4]diazepin-3-yl];~et:~mi(l~
l~N H
.
30 mp=l7l-l72t~c [a]D =+37.0~ (c=0.61; MeOH) lH NMR, CDC13, o 7.59-7.19 (m, 10H), 5.44 (d, J=8.3 Hz, lH), 4.54 (septet, J=6.9 Hz, IH), 3.54 (s, 2H), 1.49 (d, J=6.9 Hz, 3H), 1.25 (d, J=6.9 Hz, 3H).
- =
WO 96/05827 . PCT/US95J10501 ~ 21 9~7~
- Anal. Calcd. for C26H23N3o2cl2: -C, 65.01; H, 4.83; N, 8.75. Found: C, 65.00; H, 4.89; N, 8.71%.
Example 4 (+)-2-(3,5-Dichlorophenyl)-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl- I H-benzo[e] [1,4]diazepin-3 -yl]~ e~midP
N~C
mp=90-96~C
[a]D = +42.7~ (c=0.71; MeOH) lH NMR, CDC13, ~ 7.59-7.19 (m, 10H), 5.44 (d, J=8.3 Hz, IH), 20 4 54 (septet, J=6.9 Hz, lH), 3.54 (s, 2H), 1.49 (d, J=6.9 Hz, 3H), 1.25 (d, J=6.9 Hz, 3H).
Anal. Calcd. for C26H23N3O2C12-0.20 H20:
C, 64.52; H, 4.87; N, 8.68. Found: C, 64.55; H, 5.00; N, 8.54~o.
Fx~ ?le5 (+)-3-(2,4-Dichlorophenyl)-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]~..,pdlldlllide WO 96/05827 . 2 ~ 9 5 9 7 3 PCTNS95/10501 ~
N Y ~
¢~cN H Cl 10 m.p. 138-139 ~C, [a]D = +70.9" (c=0.79; MeOH).
Anal. Calcd. for C27H25N302C12:
C,65.59;H,5.1;N,8.5.Found:C,65.21;H,5.1;N,8.6%.
Examyle 6 (-)-3-(2,4-Dichlorophenyl)-N-[3S-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~ an~llide -~ , m.p. 142-143 ~C, [a]D = -66.3~ (c=0.64; MeOH).
Anal. Calcd. for C27H25N3o2cl2.:
C, 65.59; H, 5.1; N, 8.5. Found: C, 65.51; H, 5.04; N, 8.65%.
F~mrle 7 (-)-3-(3,4-Dichloro)-N-[3S-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl- 1 H-benzo[e][1,4]diazepin-3-yl]bPn7~mi~
~ WO 96/05827 . PCT/US95/10501 -- 21 9~9~3 H J~
10 m.p. 143-144 ~C, [a]D = -72.2~ (c=0.45; MeOH).
Anal. Calcd. for C25H21N3O2C12-0.55 mol cyclohexane:
C, 66.3; H, 5.43; N, 8.2. Found: C, 66.31; H, 5.49; N, 8.19%.
Example 8 (+)-2-(A-i~m:lnt~n-1 -yl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]~ret:~mi~1r ¢~, m.p. 176-177 ~C, [oc]D = +63.5~ (c=0.51; MeOH).
Anal. Calcd. for C30H3sN3o2:
C, 76.73; H, 7.51; N, 8.95. Found: C, 76.39; H, 7.46; N, 8.86~o.
Fx~mple 9 (+)4-Cyclohexyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]bnt~n~mi(li~
WO 96/05827 . PCTIUS95/10501 2 ~ 95973 s ~ H
m.p. foam ~C, [~c]D = +59.1 ~ (c=0.43; MeOH)..
Anal. Calcd. for C2gH35N3O2-0.20 mol H20:
C, 74.87; H, 7.94, N, 9.35. Found: C? 74.92; H, 7.88; N, 9.35%.
Example 10 (+)-~lqm:~nt~n- I -yl-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]carboxamide N
N
m.p. 206-207 ~C, [oc]D = +38.5~ (c=0.52; MeOH).
Anal. Calcd. for C29H33N302-0.30 mol H20:
C, 75.56; H, 7.35; N, 9.11. Found: C, 75.62; H, 7.33; N, 8.91%.
Example 11 (+)-2-[3,5-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][ l ,4]diazepin-3-yl]~et~mi(lP
~ WO 96/05827 . 2 l 9 5 9 7 3 PCTrusg5rl0sol --~ C F3 ~5N H CF3 m.p. 152-153 ~C, [a]D = +37.5~ (c=0.65; MeOH).
Anal. Calcd. for C28H23N3o2F6:
C, 61.43; H, 4.23; N, 7.67. Found: C, 61.47; H, 4.22; N, 7.7~O.
Fx~n~le 12 (+)-2-(2,4-Dichlol uphcllyl)-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yllf~.ç~t~mide 2 0 ~ N
m.p. 78-84 ~C, [a]D = +26.3~ (c=0.67; MeOH).
Anal. Calcd. for C26H23N3O2C12-0.20 mol cyclohexane:
C, 65.7; H, 5.15; N, 8.45. Found: C, 65.53; H, 5.25; N, 8.35%.
- Example 13 (+)-3-Chloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][1,4]diazepin-3-yl]kPn7~mi~P
WO 96/05827 ' PCT/USgS/10501 21 95~73 N~CI
m.p. 79-86 ~C, [oc]D = +50.5~ (c=0.55; MeOH).
Anal. Calcd. for C25H22N3O2CI-0.35 mole cyclohexane:
C, 70.55; H, 5.72; N, 9.11. Found: C, 70.63; H, 5.79; N, 9.18%.
Fx~mRle 14 (+)-4-Chloro-N-[3R-2,3 -dihydro-l -(2-propyl)-2-oxo-5-phenyl- I H-benzo[e][l ,4]diazepin-3-yllbPn7s,mi~
-;~
m.p. 168-169 ~C, [a]D = +79.7" (c=0.96; MeOH).
Anal. Calcd. for C25H22N3O2CI.:
C, 69.52; H, 5.13; N, 9.73. Found: C, 69.75; H, 5.19; N, 9.9%.
Fx:~m,l?le 15 (+)-2-(3-Chlo~ h~llyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-ben_o[e][l,4]diazepin-3-yl]~ çr~mi-lP
~ WO 961058:~7 PCTIUS95/10501 ~N H
m-p- 137-139~C, [a]D= +44.2~ (c=0.60; MeOH).
Anal. Calcd. for C26H24N302CI.:
C, 70.03; H, 5.42; N, 9.42. Found: C. 70.23; H, 5.43; N, 9.45%.
Fx~mQle 16 (+)-3-Bromo-4-chloro-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]benzamide ~ N~[~Br ~
m.p. 173-175 ~C, [a]D = +58.6~ ~c=0.36; MeOH).
Anal. Calcd. for C25H20N3o2Brcl-o.4o mol H20:
C, 58.08; H, 4.06; N, 8.13. Found: C, 58.1; H, 4.14; N, 8.11%.
Example 17 (+)-3-Bromo-N-[3R-2,3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl- 1 H -benzo[e][1 ,4]diazepin-3-yl]hen7:~,mi~P
N~Br m.p. 78-85 ~C, [a]D = +50.4~ (c=0.76; MeOH).
Anal. Calcd. for C25H22N302Br 0.85 mol H20 0.30 mol cy~lnh!~x~n~:
C, 62.27; H, 5.32; N, 8.13. Found: C, 62.27; H, 5.16; N, 8.03%.
Example 18 (-)-3,5-Dichloro-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]b.on7~mi(1~o ~ H~
Cl m.p. 140-141 ~C, [a]D = -83.7~ (c=0.52; MeOH).
Anal. Calcd. for C25H2lN3o2cl2-C, 64.39; H, 4.54; N, 9.01. Found: C, 64.36; H, 4.76; N, 8.62%.
Example 19 (+)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]ben7~mi~1to ~ WO 96/05827 . PCT/US9S/10501 21 95973 ~
m.p. 216-219 ~C, [a]D +53.9~ (c=0.36; CHC13).
Anal. Calcd. for C25H23N3o2:
C, 75.55; H, 5.83; N, 10.57. Found: C, 75.9; H, 5.87; N, 10.69%.
Example 20 (+)-2-(3-Trifluoromethylphenyl)-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl]sl~ et:lmi(le -20 ¢~~ ~--~'CF3 [a]D+35.9~(c--0.41; MeOH).
Anal. Calcd. for C27H24N3o2F3:
C, 67.63; H, 5.05; N, 8.76. Found: C, 67.96; H, 5.27; N, 8.37%.
Fx:~ml?le 21 (+)-3,5-Bis(trifluoromethyl) -N- [3R-2,3 -dihydro- I -(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]bPn7~mi(ie W096/05827 . 2195973 PCI/US95110501 ~
N ~c F3 10 m.p. 198-199 ~C, [a]D +39.2~ (c=0.53; MeOH).
Anal. Calcd. for C27H21N3O2F6-0.40 mol EtOAc:
C, 60.4; H, 4.29; N, 7.39. Found: C, 60.4; H, 4.28; N, 7.42%.
Example 22 (+)-2-(2-Trifluorornethylphenyl)-N-[3R-2.3-dihydro- 1 -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]S~et:lmi~l~
-~sN H CF3 m.p. 160-162 ~C, [oc]D +32.3~ (c=0.39; MeOH).
Anal. Calcd. for C27H24N3o2F3:
C, 67.63; H, 5.05; N, 8.76. Found: C, 67.58; H, 5.1; N, 8.85%.
Example 23 (+)-2-(4-Tlinuululll~ ylluh~;llyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][1,4]diazepin-3-yl]~ref~mi~l~
~ WO 96105827 . PCT/US95/10501 s ~ N ~C F3 m.p. 227-228 ~C, [a]D +38.0~ (c=0.30; MeOH).
Anal. Calcd. for C27H24N3o2F3:
C, 67.63; H, 5.05; N, 8.76. Found: C, 67.93; H, 5.06; N, 8.98%.
lS Example 24 (+)-2-Phenyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][l ,4]diazepin-3-yl]~ret~mi~l.q ~ N~3 ~_Y
m.p. 154-156 ~C, [a]d +40.3~ (c=0.38; MeOH).
Anal. Calcd. for C26H25N3O2-0.45 mol H20:
30 C, 74.42; H, 6.22; N, 10.01. Found: C, 74.45; H, 6; N, 9.96%.
WO 96/05827 . PCT/US95/10501 Fx;~rnple 25 (-)-2-(3,5-Dichlorophenyl)-N-[3S-2,3-dihydro-1 -(2-propyl)-2-oxo-5-phenyl-lH-benzoLe][1,4]diazepin-3-yl]acetamide ~ Cl ~ H
~
m.p. foam ~C, [a]D = -39.1~ (c=0.46; MeOH).
Anal. Calcd. for C26H23N3o2cl2:
C, 65.01; H, 4.83; N, 8.75. Found: C, 64.69; H, 4.85; N, 8.559'o.
Fx~ rle 26 20 (-)-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[1 -(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-lH-benzo[e][l ,4]diazepin-3-yl]~ret~mirl~
~--~'~ N~CF3 m.p. 195-6 ~C, [a]D = -33~ (c=0.49; MeOH).
Anal. Calcd. for C27H24N303F3:
C, 65.45; H, 4.88; N, 8.48. Found: C, 65.19; H, 4.83; N, 8.35%.
~ WO 96105827 2 1 9 5 9 7 3 PCT/US95~10501 Example 27 (+)-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[1 -(2-propyl)-2-oxo-S-phenyl-2,3-dihydro-lH-benzoLe][ l ,4]diazepin-3-yl]~et~mi~
~~ ~CF3 m.p. 227-8 ~C, [oc]D = +53~ (c=0.89; MeOH).
Anal. Calcd. for C27H24N303F3:
C, 65.45; H, 4.88; N, 8.48. Found: C, 65.26; H, 4.82; N, 8.55%.
F~lmrlç 28 20 (+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-S-phenyl-lH-benzo[e][l ,4]diazepim-3-yl]~re~:~mi~
/
~N H ~F
~ ' W096/05827 2 ~ 9 5 9 73 PCTIUS95/10501 ~
Step A. 2,4-Bis(trifluoromethyl)benzonitrile To a stirring biphasic mixture of 100mL ethanol and 250mL of pho~rh~t~
buffer (Ig of NaH2PO4-H2O per 5 mL H2O adjusted to pH=7.0 with 50%
NaOH) and NaCN (81.3mmol,4.0g) heated to 60~C was added 2,4-bis(trifluoromethyl) benzyl bromide (32.5rnmol,10g) in 50mL EtOH
dropwise over 30min. The reaction was heated at 60~C for 24h. The reaction was then evaporated under reduced pressure. The remaining aqueous was extracted with 2xl50mL EtOAc. The organic layers were combined, dried with brine and Na2SO4. The organic phase was evaporated under reduced pressure and the residue chromatographed over silica eluting with 10% EtOAc:Hexanes. The pure fractions were collected and evaporated to give 7.0g of a pale yellow oil, 85.1 % NMR
H (CDCI3) o 8.0-7.85 (m,3H), 4.03 (s,2H) Step B. 2,4-Bis(trifluoromethyl)phenyl acetic acid 2,4-Bis(trifluolu~ Ll.yl)benzonitrile (41.5mmol,10.51g) was taken up in 100mL acetic acid, 50mL conc. H2SO4, and 20mL water. This was heated to 120~Cfor 3h. The reaction was then diluted with IL ice water, and extracted with 2x300mL ethyl acetate. The ct-mhin~d organics were washed with 2x200mL water, dried with brine and Na2SO4, and evaporated under reduoed pressure. The residue was taken up in a minimnm of diethyl ether and crystallized by adding sufficient hexane to precipatate the product. The solid was collected to give 7.74g of 2,4-bis(trifluoromethyl) phenyl acetic acid as white crystals, 68.5%.NMR IH
(CDCI3) ~ 7.93 ~s,lH), 7.80 (d, J=7.9Hz,lH), 7.55 (d, J=7.9Hz,lH), 3.94 (s,2H).
Step C: (+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-I -(2-propyl)-2-oxo-5-phenyl-lH-benzo[e][1,4]diazepin-3-yl] ~ oet~mi(l~
The 2,4-Bis-(trifluoromethyl) phenyl acetic acid obtained in step B
Wo 96/05827 . PCI/US95/10501 ~ was coupled with 3R-3-Amino-2,3-dihydro- 1- (2-propyl)-2-oxo-5-phenyl-lH-benzo[e][ 1 ,4]diazepine from step E example I by a procedure suh~t~nti~lly as desribed for step F example I to give (+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1 -(2-propyl)-2-oxo-5-5 phenyl-lH-benzo[e][1,4]diazepin-3-yl]-:~ret~,mi~P
m.p. 134-136 ~C, [a]D = +22~ (c=0.39; MeOH).
Anal. Calcd. for C28H23N3o2F3:
C,61.43;H,4.23;N,7.67.Found:C,61.61;H,4.24;N,7.75%.
The following examples were prepared by procedures ~ub~ lially as described in example I except sl-hstihltin~ the ~ -vpri~-te fluoro suh~titllt~d aminobenzophenone in step A.
Example 29 (+)-3-Cyclohexyl-N-[2,3-dihydrol -(2-propyl)-2-oxo-5-(4-fluoprophenyl)-lH-benzo[e][l,4]diazepim-3-yl]~"v~u~ lide ~
F
mp=179-181~C
[a]D=+45.1~ (c=0.55; MeOH) Anal. Calcd. for C27H32FN302:
C, 72.14; H, 7.17; N, 9.35. Found: C, 71.98; H, 7.10; N, 9.43%.
WO 96/05827 2 ~ 9 5 9 7 3 PCTIUS95/10501 ~
Example 30 (+)-3-S-Dichloro-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(4-fluorophenyl)-I H-benzo[e] [ I ,4]diazepin-3-yl]benzamide o ~ Cl m.p. 174-176 ~C, [a]D +53.9~ (c=0.36; CHC13).
Anal. Calcd. for C25H2ocl2FN3o2:
C, 61.54; H, 4.21; N, 8.61. Found: C, 61.54; H, 4.22; N, 8.72 Example 31 3-Cyclohexyl -N-r2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(2-fluorophenyl)- I H -benzo[e] [ l ,4]diazepin-3-yl]~ ,pallal-lide ~~ O
25 ~ Jl o /~F
m.p. 165-167 ~C.
Anal. Calcd. for C27H32N302F:
C,72.14;H,7.17;N,9.35.Found:C,71.71;H,7.11;N,9.33%.
~59;,73 ~xample 32 3,4-Dichloro-N-[2,3-dihydro- 1 -(2-propyl)-2-oxo-5-(2-fluorophenyl)- I H-benzo[e][l ,4]diazepin-3-yl]b.on7~mi~1e '~ J~c F
m.p. l 88-189 ~C.
15 Anal. Calcd. for C25H2oN3o2cl2F~:
C,61.99; H,4.16; N, 8.68. Found: C, 61.7; H,4.22; N,8.59%.
Claims (15)
1. A compound of the structural formula I
FORMULA I
where R1 is or ;
X and Y are independently hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl;
n is 0, 1 or 2; and R2 is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy;
as the racemates, mixtures of enantiomers, individual diastereomers or individual enantiomers, and pharmaceutically acceptable crystal forms, salts, or hydrates thereof.
FORMULA I
where R1 is or ;
X and Y are independently hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl;
n is 0, 1 or 2; and R2 is hydrogen, fluoro, chloro, bromo, iodo, or trifluoromethyl, methyl, or methoxy;
as the racemates, mixtures of enantiomers, individual diastereomers or individual enantiomers, and pharmaceutically acceptable crystal forms, salts, or hydrates thereof.
2. The compound of Claim 1 selected from the group consisting of (+)-3,5-Dichloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide.
;
(+)-3-Cyclohexyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]propanamide ;
(+)-2-(3,4-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-(3,5-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[1-(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3-(2,4-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]propanamide ;
(-)-3-(2,4-Dichlorophenyl)-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]propanamide ;
(-)-3,4-Dichloro-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-2-Adamantan-1-yl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-4-Cyclohexyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]butanamide ;
(+)-Adamantan-1-yl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]carboxamide ;
(+)-2-[3,5-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-(2,4-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3-Chloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-4-Chloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-2-(3-Chlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3-Bromo-4-chloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
3,4-Dichloro-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-(2-fluorophenyl)-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-3-Bromo-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
3-(Cyclohexyl)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-(2-fluorophenyl)-1H-benzo[e][1,4]diazepin-3-yl]propanamide ;
(-)-3,5-Dichloro-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-2-(3-Trifluoromethylphenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3,5-Bis(trifluoromethyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-2-(2-Trifluoromethylphenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-(4-Trifluoromethylphenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-Phenyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(-)-2-(3,5-Dichlorophenyl)-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(-)-3R-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[1-(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3R-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[1-(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3-Cyclohexyl-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-(4-fluoprophenyl)1H-benzo[e][1,4]diazepin-3-yl]propanamide ; and (+)-3-5-(Dichloro)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-3-yl]benzamide
;
(+)-3-Cyclohexyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]propanamide ;
(+)-2-(3,4-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-(3,5-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-[2,4-Bis(trifluoromethyl)phenyl]-N-[1-(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3-(2,4-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]propanamide ;
(-)-3-(2,4-Dichlorophenyl)-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]propanamide ;
(-)-3,4-Dichloro-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-2-Adamantan-1-yl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-4-Cyclohexyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]butanamide ;
(+)-Adamantan-1-yl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]carboxamide ;
(+)-2-[3,5-Bis(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-(2,4-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3-Chloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-4-Chloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-2-(3-Chlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3-Bromo-4-chloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
3,4-Dichloro-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-(2-fluorophenyl)-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-3-Bromo-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
3-(Cyclohexyl)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-(2-fluorophenyl)-1H-benzo[e][1,4]diazepin-3-yl]propanamide ;
(-)-3,5-Dichloro-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-2-(3-Trifluoromethylphenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3,5-Bis(trifluoromethyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide ;
(+)-2-(2-Trifluoromethylphenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-(4-Trifluoromethylphenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-2-Phenyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(-)-2-(3,5-Dichlorophenyl)-N-[3S-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(-)-3R-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[1-(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3R-2-Hydroxy-2-(4-trifluoromethylphenyl)-N-[1-(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide ;
(+)-3-Cyclohexyl-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-(4-fluoprophenyl)1H-benzo[e][1,4]diazepin-3-yl]propanamide ; and (+)-3-5-(Dichloro)-N-[2,3-dihydro-1-(2-propyl)-2-oxo-5-(4-fluorophenyl)-1H-benzo[e][1,4]diazepin-3-yl]benzamide
3. The compound of Claim 1 which is (+)-3,5-Dichloro-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]benzamide.
.
.
4. The compound of Claim 1 which is (+)-3-Cyclohexyl-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]propanamide .
5. The compound of Claim 1 which is (+)-2-(3,4-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide
6. The compound of Claim 1 which is (+)-2-(3,5-Dichlorophenyl)-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1H-benzo[e][1,4]diazepin-3-yl]acetamide
7. The compound of Claim 1 which is (+)-2-[2,4-Bis-(trifluoromethyl)phenyl]-N-[3R-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl]acetamide
8. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of Claim 1 or a pharmaceutically acceptable salt, crystal form or hydrate thereof.
9. The pharmaceutical formulation of Claim 8 comprising in addition another antiarrhythmic agent or other cardiovascular agent.
10. A method of preventing or treating arrhythmia which comprises the administration to a patient in need of such treatment of an antiarrhythmically effective amount of the compound of Claim 1.
11. The method of Claim 10 comprising the concomitant administration of another antiarrhythimic agent or other cardiovascular agent.
12. A pharmaceutical formulation comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound of Claim 7 or a pharmaceutically acceptable salt, crystal form or hydrate thereof.
13. The pharmaceutical formulation of Claim 7 comprising in addition another antiarrhythmic agent or other cardiovascular agent.
14. A method of preventing or treating arrhythmia which comprises the administration to a patient in need of such treatment of an antiarrhythmically effective amount of the compound of Claim 7.
15. The method of Claim 14 comprising the concomitant administration of another antiarrhythimic agent or other cardiovascular agent.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29244994A | 1994-08-18 | 1994-08-18 | |
US292,449 | 1994-08-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2195973A1 true CA2195973A1 (en) | 1996-02-29 |
Family
ID=23124720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002195973A Abandoned CA2195973A1 (en) | 1994-08-18 | 1995-08-17 | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines |
Country Status (6)
Country | Link |
---|---|
US (1) | US5633251A (en) |
EP (1) | EP0776203A4 (en) |
JP (1) | JP2000504306A (en) |
AU (1) | AU692916B2 (en) |
CA (1) | CA2195973A1 (en) |
WO (1) | WO1996005827A1 (en) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997048686A1 (en) * | 1996-06-21 | 1997-12-24 | Merck & Co., Inc. | Novel n-1 alkyl-2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amides |
US5776930A (en) * | 1996-06-28 | 1998-07-07 | Merck & Company, Inc. | Pharmaceutical preparation |
EP0907644A4 (en) * | 1996-06-28 | 2003-02-05 | Merck & Co Inc | Pharmaceutical preparation |
US5929071A (en) * | 1996-07-02 | 1999-07-27 | Merck & Co., Inc. | Method for the treatment of preterm labor |
WO1998000406A1 (en) * | 1996-07-02 | 1998-01-08 | Merck & Co., Inc. | Method for the treatment of preterm labor |
US6683075B1 (en) | 1996-12-23 | 2004-01-27 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use |
US6635632B1 (en) * | 1996-12-23 | 2003-10-21 | Athena Neurosciences, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US5817658A (en) * | 1997-03-14 | 1998-10-06 | Merck & Company, Inc. | Method for treating Meniere's disease |
US6100254A (en) * | 1997-10-10 | 2000-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of protein tyrosine kinases |
EP1024811A4 (en) * | 1997-10-17 | 2002-11-13 | Merck & Co Inc | Novel benzodiazepine derivatives as antiarrhythmic agents |
US6214823B1 (en) | 1997-10-17 | 2001-04-10 | Merck & Co., Inc. | Benzodiazepine derivatives as antiarrhythmic agents |
US6569851B1 (en) | 1998-06-22 | 2003-05-27 | Elan Pharmaceutials, Inc. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6958330B1 (en) | 1998-06-22 | 2005-10-25 | Elan Pharmaceuticals, Inc. | Polycyclic α-amino-ε-caprolactams and related compounds |
US6528505B1 (en) | 1998-06-22 | 2003-03-04 | Elan Pharmaceuticals, Inc. | Cyclic amino acid compounds pharmaceutical compositions comprising same and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6552013B1 (en) | 1998-06-22 | 2003-04-22 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US6774125B2 (en) * | 1998-06-22 | 2004-08-10 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
US20060025388A1 (en) | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
CA2372150C (en) | 1999-04-30 | 2011-08-30 | The Regents Of The University Of Michigan | Therapeutic applications of pro-apoptotic benzodiazepines |
US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
US7572788B2 (en) * | 1999-04-30 | 2009-08-11 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
DE19938736A1 (en) * | 1999-08-16 | 2001-02-22 | Bayer Ag | Process for the preparation of [bis (trifluoromethyl) phenyl] acetic acids and their alkyl esters and [bis (trifluoromethyl) phenyl] malonic acid dialkyl ester |
US6503902B2 (en) * | 1999-09-13 | 2003-01-07 | Bristol-Myers Squibb Pharma Company | Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production |
CA2404273A1 (en) * | 2000-04-11 | 2001-10-18 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of a.beta. protein production |
US20100009966A1 (en) * | 2001-04-11 | 2010-01-14 | Bristol-Myers Squibb Pharma Company | Substituted lactams as inhibitors of abeta protein production |
US20050192265A1 (en) * | 2003-03-20 | 2005-09-01 | Thompson Richard C. | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds |
US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
AU2006203946B2 (en) | 2005-01-03 | 2009-07-23 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
JP2008545757A (en) * | 2005-06-01 | 2008-12-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Unsolvated benzodiazepine compositions and methods |
EP1928465A1 (en) * | 2005-09-19 | 2008-06-11 | Arrow Therapeutics Limited | Benzodiazepine derivatives for treating hepatitis c infection |
EP1948191B1 (en) | 2005-11-01 | 2013-01-16 | The Regents of the University of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
US8097612B2 (en) * | 2006-06-09 | 2012-01-17 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
CA2783589A1 (en) * | 2007-03-09 | 2008-09-18 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
CN101855203B (en) | 2007-09-14 | 2014-03-19 | 密执安州立大学董事会 | F1F0-ATPase inhibitors and related methods |
NZ584842A (en) | 2007-11-06 | 2012-06-29 | Univ Michigan | Benzodiazepinone compounds useful in the treatment of skin conditions, in particular, psoriasis |
US8497307B2 (en) | 2008-09-11 | 2013-07-30 | The Regents Of The University Of Michigan | Aryl guanidine F1F0-ATPase inhibitors and related methods |
WO2010121164A2 (en) | 2009-04-17 | 2010-10-21 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
JP2013505258A (en) | 2009-09-18 | 2013-02-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | Benzodiazepinone compounds and therapeutic methods using the same |
CA2780333C (en) | 2009-11-17 | 2016-05-24 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
ES2703752T3 (en) | 2009-11-17 | 2019-03-12 | Univ Michigan Regents | 1,4-Benzodiazepine-2,5-diones and related compounds that exhibit therapeutic properties |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4820834A (en) * | 1984-06-26 | 1989-04-11 | Merck & Co., Inc. | Benzodiazepine analogs |
CA1332410C (en) * | 1984-06-26 | 1994-10-11 | Roger M. Freidinger | Benzodiazepine analogs |
US5166151A (en) * | 1988-03-25 | 1992-11-24 | Merck & Co., Inc. | 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof |
US5324726A (en) * | 1989-12-18 | 1994-06-28 | Merck & Co., Inc. | Benzodiazepine analogs |
US5220018A (en) * | 1991-04-10 | 1993-06-15 | Merck & Co., Inc. | Cholecystokinin antagonists |
CA2068355A1 (en) * | 1991-05-14 | 1992-11-15 | Mark S. Chambers | Benzodiazephine derivatives, compositions containing them and their use in therapy |
GB9116113D0 (en) * | 1991-07-25 | 1991-09-11 | Merck Sharp & Dohme | Therapeutic agents |
US5153191A (en) * | 1991-08-20 | 1992-10-06 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
WO1993007131A1 (en) * | 1991-10-10 | 1993-04-15 | Merck Sharp & Dohme Limited | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors |
AU2759692A (en) * | 1991-10-24 | 1993-05-21 | Glaxo Group Limited | Benzodiazepine derivatives as antagonists of gastrin and/or cholecystokinin |
WO1993008176A1 (en) * | 1991-10-24 | 1993-04-29 | Merck Sharp & Dohme Limited | Benzodiazepine derivatives and their use as antagonists of cholecystokinin and/or gastrin receptors |
US5428031A (en) * | 1991-12-03 | 1995-06-27 | Merck & Co., Inc. | Methods of treating cardiac arrhythmia |
GB9203790D0 (en) * | 1992-02-21 | 1992-04-08 | Merck Sharp & Dohme | Therapeutic agents |
US5597915A (en) * | 1992-03-16 | 1997-01-28 | Merck Sharp & Dohme Ltd. | Benzodiazepine derivatives, compositions containing them and their use in therapy |
US5426185A (en) * | 1993-11-22 | 1995-06-20 | Merck & Co., Inc. | Antiarrhythmic benzodiazepines |
-
1995
- 1995-08-17 JP JP8508204A patent/JP2000504306A/en active Pending
- 1995-08-17 WO PCT/US1995/010501 patent/WO1996005827A1/en not_active Application Discontinuation
- 1995-08-17 AU AU33304/95A patent/AU692916B2/en not_active Ceased
- 1995-08-17 CA CA002195973A patent/CA2195973A1/en not_active Abandoned
- 1995-08-17 US US08/516,467 patent/US5633251A/en not_active Expired - Fee Related
- 1995-08-17 EP EP95929602A patent/EP0776203A4/en not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
US5633251A (en) | 1997-05-27 |
JP2000504306A (en) | 2000-04-11 |
WO1996005827A1 (en) | 1996-02-29 |
EP0776203A1 (en) | 1997-06-04 |
AU3330495A (en) | 1996-03-14 |
AU692916B2 (en) | 1998-06-18 |
EP0776203A4 (en) | 1997-12-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2195973A1 (en) | N-2,3-dihydro-1-(2-propyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines | |
US5658901A (en) | 2,3-dihydro-1-(2,2,2,-trifluoroethyl)-2-oxo-5-phenyl-1H-1,4-benzodiazepines | |
EP0830350B1 (en) | n-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1h-benzo[b][1,5]diazepin-3-yl)-acetamides | |
AU704220B2 (en) | Novel 5-cyclopropyl-1,4 benzodiazepine-2-ones | |
AU720378B2 (en) | Novel N-(4-oxo-2,3,4,5-tetrahydro-1H-1, 5-benzodiazepin-3yl)-3-amides | |
AU722110B2 (en) | Pharmaceutical preparation | |
AU5968896A (en) | Novel N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1, 5-benzodiazepin-3YL)-3-amides | |
AU703665B2 (en) | Novel N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3 yl)-3-amides | |
US5776930A (en) | Pharmaceutical preparation | |
WO1997048686A1 (en) | Novel n-1 alkyl-2-oxo-2,3,4,5-tetrahydro-1h-1,5-benzodiazepin-3-yl)-3-amides | |
WO1997049690A1 (en) | A method for treating meniere's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |